UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
For the transition period from ________________ to ________________.
Commission File Number
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of Incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
|
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | None | None |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated Filer ☐ | Accelerated Filer ☐ | |
| Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
As of July 31, 2022, the Registrant had shares of Common Stock outstanding.
TABLE OF CONTENTS
| Page | ||
| Part I – FINANCIAL INFORMATION | ||
| Cautionary Note About Forward Looking Statements | 3 | |
| Item 1. | Financial Statements | 4 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 36 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 46 |
| Item 4. | Controls and Procedures | 46 |
| Part II – OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 47 |
| Item 1A. | Risk Factors | 47 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 48 |
| Item 3. | Defaults Upon Senior Securities | 48 |
| Item 4. | Mine Safety Disclosures | 48 |
| Item 5. | Other Information | 48 |
| Item 6. | Exhibits | 48 |
| Signatures | 49 | |
| 2 |
CAUTIONARY NOTE ABOUT FORWARD-LOOKING INFORMATION
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy and plans, and objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “become,” “develop,” “build,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual events or our actual results, performance or achievements to be materially different from the future events, results, performance or achievements expressed or implied by any forward-looking statements. There can be no assurance that future events, results, performance or achievements will be in accordance with our expectations or that the effect of future events, results, performance or achievements will be those anticipated by us.
Factors and risks that may cause or contribute to actual events, results, performance or achievements differing from these forward-looking statements include, but are not limited to, for example:
| · | regulatory limitations on our products and services; |
| · | our ability to identify, consummate, and integrate anticipated acquisitions; |
| · | general industry and economic conditions; |
| · | our ability to access adequate capital upon terms and conditions that are acceptable to us; |
| · | our ability to pay interest and principal on outstanding debt when due; |
| · | volatility in credit and market conditions; and |
| · | other risks and uncertainties related to the cannabis market and our business strategy. |
We operate in very competitive and rapidly changing markets. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this Quarterly Report on Form 10-Q are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved.
These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements concerning other matters addressed in this Quarterly Report on Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Quarterly Report on Form 10-Q.
All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether because of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
| 3 |
Part I. FINANCIAL INFORMATION
Item 1. Condensed Financial Statements
MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Audited) | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net of allowance for doubtful accounts | ||||||||
| Inventory | ||||||||
| Note receivable - current, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets | ||||||||
| Fixed assets, net accumulated depreciation of $ | ||||||||
| Goodwill | ||||||||
| Intangible assets, net accumulated amortization of $ | ||||||||
| Marketable securities, net of unrealized loss of $ | ||||||||
| Note receivable – noncurrent, net | ||||||||
| Accounts receivable – litigation | ||||||||
| Other noncurrent assets | ||||||||
| Operating lease right of use assets | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accounts payable - related party | ||||||||
| Accrued expenses | ||||||||
| Derivative liabilities | ||||||||
| Notes payable - related party | ||||||||
| Lease liabilities - current | ||||||||
| Income taxes payable | ||||||||
| Total current liabilities | ||||||||
| Long term debt | ||||||||
| Lease liabilities | ||||||||
| Total long-term liabilities | ||||||||
| Total liabilities | ||||||||
| Stockholders' equity | ||||||||
| Common stock, $par value. shares authorized; shares issued and shares outstanding at June 30, 2022 and shares issued and shares outstanding as of December 31, 2021. | ||||||||
| Preferred stock, $par value. shares authorized; shares issued and outstanding at June 30, 2022 and December 31, 2021. | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Common stock held in treasury, at cost, shares held as of June 30, 2022 and shares held as of December 31, 2021 | ( | ) | ( | ) | ||||
| Total stockholders' equity | ||||||||
| Total liabilities and stockholders' equity | $ | $ | ||||||
See accompanying notes to the financial statements
| 4 |
MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME
For the Periods Ended June 30, 2022 and 2021
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Operating revenues | ||||||||||||||||
| Retail | $ | $ | $ | $ | ||||||||||||
| Wholesale | ||||||||||||||||
| Other | ||||||||||||||||
| Total revenue | ||||||||||||||||
| Cost of goods and services | ||||||||||||||||
| Total cost of goods and services | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative expenses | ||||||||||||||||
| Professional services | ||||||||||||||||
| Salaries | ||||||||||||||||
| Stock based compensation | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Income (loss) from operations | ||||||||||||||||
| Other income (expense) | ||||||||||||||||
| Interest income (expense), net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Unrealized gain (loss) on derivative liabilities | ||||||||||||||||
| Other income (expense) | ||||||||||||||||
| Gain (loss) on sale of assets | ||||||||||||||||
| Unrealized gain (loss) on investments | ( | ) | ( | ) | ||||||||||||
| Total other income (expense) | ( | ) | ||||||||||||||
| Provision for income taxes (benefit) | ||||||||||||||||
| Net income (loss) | $ | $ | $ | $ | ||||||||||||
| Less: Accumulated preferred stock dividends for the period | ( | ) | ( | ) | ||||||||||||
| Net income (loss) attributable to common stockholders | $ | $ | $ | $ | ||||||||||||
| Earnings (loss) per share attributable to common shareholders | ||||||||||||||||
| Basic earnings (loss) per share | $ | $ | $ | $ | ||||||||||||
| Diluted earnings (loss) per share | $ | $ | $ | $ | ||||||||||||
| Weighted average number of shares outstanding - basic | ||||||||||||||||
| Weighted average number of shares outstanding - diluted | ||||||||||||||||
| Comprehensive income (loss) | $ | $ | $ | $ | ||||||||||||
See accompanying notes to the financial statements
| 5 |
MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
For the Periods Ended June 30, 2022 and 2021
| Preferred Stock | Common Stock | Additional Paid in | Accumulated | Treasury Stock | Total Stockholders’ | ||||||||||||||||||||||
| Shares | Value | Shares | Value | Capital | Deficit | Shares | Cost | Equity | |||||||||||||||||||
| Balance, December 31, 2020 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||
| Net income (loss) | – | – | – | ||||||||||||||||||||||||
| Issuance of stock as payment for acquisitions | – | – | |||||||||||||||||||||||||
| Return of common stock as compensation to employees, officers and/or directors | – | – | – | ||||||||||||||||||||||||
| Issuance of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of preferred stock in connection with sales made under private or public offerings | – | – | |||||||||||||||||||||||||
| Dividends declared | – | – | – | ||||||||||||||||||||||||
| Conversion of preferred stock to common stock | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||
| Return of common stock | – | – | ( | ) | ( | ) | |||||||||||||||||||||
| Stock based compensation expense related to common stock options | – | – | – | ||||||||||||||||||||||||
| Balance, June 30, 2021 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||
| Preferred Stock | Common Stock | Additional Paid in | Accumulated | Treasury Stock | Total Stockholders’ | ||||||||||||||||||||||
| Shares | Value | Shares | Value | Capital | Deficit | Shares | Cost | Equity | |||||||||||||||||||
| Balance, December 31, 2021 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||
| Net income (loss) | – | – | – | ||||||||||||||||||||||||
| Issuance of stock as payment for acquisitions | – | – | |||||||||||||||||||||||||
| Return of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of common stock in connection with sales made under private or public offerings | – | – | – | ||||||||||||||||||||||||
| Dividends declared | – | – | – | ||||||||||||||||||||||||
| Conversion of preferred stock to common stock | – | – | – | ||||||||||||||||||||||||
| Return of common stock | – | – | ( | ) | ( | ) | |||||||||||||||||||||
| Stock based compensation expense related to common stock options | – | – | – | ||||||||||||||||||||||||
| Balance, June 30, 2022 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
See accompanying notes to the financial statements
| 6 |
MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
For the Periods Ended June 30, 2022 and 2021
| Preferred Stock | Common Stock | Additional Paid in | Accumulated | Treasury Stock | Total Stockholders’ | ||||||||||||||||||||||
| Shares | Value | Shares | Value | Capital | Deficit | Shares | Cost | Equity | |||||||||||||||||||
| Balance, March 31, 2021 | $ | $ | $ | $ | ( | ) | 488,220 | $ | ( | ) | $ | ||||||||||||||||
| Net income (loss) | – | – | – | ||||||||||||||||||||||||
| Issuance of stock as payment for acquisitions | – | – | – | ||||||||||||||||||||||||
| Return of common stock as compensation to employees, officers and/or directors | – | – | – | ||||||||||||||||||||||||
| Issuance of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of preferred stock in connection with sales made under private or public offerings | – | – | – | ||||||||||||||||||||||||
| Dividends declared | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||
| Conversion of preferred stock to common stock | – | – | – | ||||||||||||||||||||||||
| Return of common stock | – | – | 28,824 | ( | ) | ( | ) | ||||||||||||||||||||
| Stock based compensation expense related to common stock options | – | – | – | ||||||||||||||||||||||||
| Balance, June 30, 2021 | $ | $ | $ | $ | ( | ) | 517,044 | $ | ( | ) | $ | ||||||||||||||||
| Preferred Stock | Common Stock | Additional Paid in | Accumulated | Treasury Stock | Total Stockholders’ | ||||||||||||||||||||||
| Shares | Value | Shares | Value | Capital | Deficit | Shares | Cost | Equity | |||||||||||||||||||
| Balance, March 31, 2022 | $ | $ | $ | $ | ( | ) | 517,044 | $ | ( | ) | $ | ||||||||||||||||
| Net income (loss) | – | – | – | ||||||||||||||||||||||||
| Issuance of stock as payment for acquisitions | – | – | |||||||||||||||||||||||||
| Return of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of common stock as compensation to employees, officers and/or directors | – | – | |||||||||||||||||||||||||
| Issuance of common stock in connection with sales made under private or public offerings | – | – | – | ||||||||||||||||||||||||
| Dividends declared | – | – | – | ||||||||||||||||||||||||
| Conversion of preferred stock to common stock | – | – | – | ||||||||||||||||||||||||
| Return of common stock | – | – | – | ||||||||||||||||||||||||
| Stock based compensation expense related to common stock options | – | – | ( | ) | 369,415 | ( | ) | ( | ) | ||||||||||||||||||
| Balance, June 30, 2022 | $ | $ | $ | $ | ( | ) | 886,459 | $ | ( | ) | $ | ||||||||||||||||
See accompanying notes to the financial statements
| 7 |
MEDICINE MAN TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
For the Periods Ended June 30, 2022 and 2021
| For the Six Months Ended | ||||||||
| June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income (loss) for the period | ||||||||
| Adjustments to reconcile net income to cash provided by (used in) operating activities | ||||||||
| Depreciation and amortization | ||||||||
| Gain on change in derivative liabilities | ( | ) | ( | ) | ||||
| Loss (gain) on investment, net | ( | ) | ||||||
| Loss (gain) loss on sale of asset | ( | ) | ||||||
| Stock based compensation | ||||||||
| Changes in operating assets and liabilities (net of acquired amounts): | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventory | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Other assets | ( | ) | ( | ) | ||||
| Operating leases right of use assets and liabilities | ||||||||
| Accounts payable and other liabilities | ||||||||
| Deferred Revenue | ( | ) | ||||||
| Income taxes payable | ( | ) | ||||||
| Net cash provided by (used in) operating activities | ( | ) | ||||||
| Cash flows from investing activities: | ||||||||
| Cash consideration for acquisition of business | ( | ) | ( | ) | ||||
| Purchase of fixed assets | ( | ) | ( | ) | ||||
| Issuance of notes receivable | ||||||||
| Purchase of intangible assets | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of debt | ||||||||
| Debt issuance and discount costs | ||||||||
| Repayment of notes payable | ( | ) | ||||||
| Proceeds from issuance of common stock, net of issuance costs | ||||||||
| Net cash provided by financing activities | ||||||||
| Net increase (decrease) in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | ||||||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Common stock issued in connection with acquisitions | ||||||||
| Issuance of common stock | ||||||||
| Return of common stock | ||||||||
See accompanying notes to the financial statements
| 8 |
MEDICINE MAN TECHNOLOGIES, INC.
NOTES TO UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS
Organization and Nature of Operations
Medicine Man Technologies, Inc. (“we,” “us,” “our” or the “Company”) was incorporated in Nevada on March 20, 2014. On May 1, 2014, we entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corp., dba Medicine Man Denver (“Medicine Man Denver”) pursuant to which Medicine Man Denver granted us a license to use all of the proprietary processes that it had developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) for 10 years.
In 2017, the Company acquired additional cultivation intellectual property through the acquisition of Success Nutrients™ and Pono Publications, including the rights to the book titled “Three A Light” and its associated cultivation techniques, which have been part of the Company’s products and services offerings since the acquisition. The Company acquired Two J’s LLC d/b/a The Big Tomato (“The Big Tomato”) in 2018, which operates a retail location in Aurora, Colorado. It has been a leading supplier of hydroponics and indoor gardening supplies in the metro Denver area since May 2001. The Company was focused on cannabis dispensary and cultivation consulting and providing equipment and nutrients to cannabis cultivators until its first plant touching acquisition in April of 2020. In 2019, due to the changes in Colorado law permitting non-Colorado resident and publicly traded investment into “plant-touching” cannabis companies, the Company made a strategic decision to move toward direct plant-touching operations. The Company developed a plan to roll up a number of direct plant-touching dispensaries, manufacturing facilities, and cannabis cultivations with a target to be one of the largest seed to sale cannabis businesses in Colorado. In April 2020, the Company acquired its first plant-touching business, Mesa Organics Ltd. (“Mesa Organics”), which consists of four dispensaries and one manufacturing infused products facility, d/b/a Purplebee’s.
On April 20, 2020, the Company rebranded and since then conducts its business under the trade name, Schwazze. The corporate name of the Company continues to be Medicine Man Technologies, Inc. Effective April 21, 2020, the Company commenced trading under the OTC ticker symbol SHWZ.
On December 17, 2020, the Company acquired the assets of (i) Starbuds Pueblo LLC, and (ii) Starbuds Alameda LLC under separate asset purchase agreements. On December 18, 2020, the Company acquired the assets of (i) Starbuds Commerce City LLC, (ii) Lucky Ticket LLC, (iii) Starbuds Niwot LLC, and (iv) LM MJC LLC under separate asset purchase agreements. On February 4, 2021, the Company acquired the assets of (i) Colorado Health Consultants LLC, and (ii) Mountain View 44th LLC under separate asset purchase agreements. On March 2, 2021, the Company acquired the assets of (i) Starbuds Aurora LLC, (ii) SB Arapahoe LLC, (iii) Citi-Med LLC, (iv) Starbuds Louisville LLC, and (v) KEW LLC under separate asset purchase agreements. The Company refers to the counterparties to these transactions as “Star Buds” and this series of acquisitions as the “Star Buds Acquisition.”
In addition, on December 16, 2020, the Company
issued and sold a Convertible Promissory Note and Security Agreement in the original principal amount of $
Between December 16, 2020 and March 30, 2021, the Company issued 57,760 shares of Preferred Stock to accredited investors in a private placement.
On July 21, 2021, the Company acquired the assets of Southern Colorado Growers under the applicable asset purchase agreement.
| 9 |
On December 3, 2021, the Company and all the
Subsidiary Guarantors (as defined in the Indenture (as defined below)) entered into a Securities Purchase Agreement with 31
accredited investors (the “Note Investors”), pursuant to which the Company agreed to issue and sell to the Note
Investors 13% senior secured convertible notes due December 7, 2026 (the “Investor Notes”) in an aggregate principal
amount of $
On December 21, 2021, the Company acquired the assets of Smoking Gun, LLC and Smoking Gun Land Company, LLC (collectively, “Smoking Gun”) under the applicable asset purchase agreement.
On January 26, 2022, the Company acquired the assets BG3 Investments, LLC, dba Drift (“Drift”), and Black Box Licensing, LLC under the applicable asset purchase agreement.
On February 8, 2022, the Company acquired its New Mexico business under the terms of a Purchase Agreement, dated November 29, 2021, with Nuevo Holding, LLC and Nuevo Elemental Holding, LLC, both of which are indirect wholly-owned subsidiaries of the Company (collectively, the “Nuevo Purchasers”), Reynold Greenleaf & Associates, LLC (“RGA”), Elemental Kitchen and Laboratories, LLC (“Elemental”), the equity holders of RGA and Elemental, and William N. Ford, in his capacity as Representative, as amended on February 8, 2022 (the “Nuevo Purchase Agreement”). The Nuevo Purchasers acquired substantially all of the operating assets of RGA and all of the equity of Elemental and assumed specified liabilities of RGA and Elemental. Pursuant to existing laws and regulations in New Mexico, the cannabis licenses for certain facilities managed by RGA are held by two not-for-profit entities: Medzen Services, Inc. (“Medzen”) and R. Greenleaf Organics, Inc. (“R. Greenleaf” and together with Medzen, the “NFPs”). At the closing, Nuevo Holding, LLC gained control over the NFPs by becoming the sole member of each of the NFPs and replacing the directors of the two NFPs with Justin Dye, the Company’s Chief Executive Officer and one of its directors, Nancy Huber, the Company’s Chief Financial Officer, and Dan Pabon, the Company’s General Counsel, Chief Government Affairs Officer and Corporate Secretary. The business acquired from RGA consists of serving as a branding, marketing and consulting company, licensing certain intellectual property related to the business of THC-based products to Elemental and the NFPs, providing consulting services to Elemental and the NFPs, and supporting Elemental and the NFPs to promote, support, and develop sales and distribution of products. Elemental is engaged in the business of creating and distributing cannabis-derived products to licensed cannabis producers. Elemental and the NFPs are in the business of cultivating, processing and dispensing marijuana in New Mexico, with 10 dispensaries, four cultivation facilities (three operating and one under development) and one manufacturing facility. The dispensaries are located in Albuquerque, Santa Fe, Roswell, Las Cruces, Grants and Las Vegas, New Mexico. The cultivation and manufacturing facilities are located in Albuquerque, New Mexico and consists of approximately 70,000 square feet of cultivation and 6,000 square feet of manufacturing. On the same date, Nuevo Holding, LLC entered into two separate Call Option Agreements containing substantially identical terms with each of the NFPs. Each Call Option Agreement gives Nuevo Holding, LLC the right to acquire 100% of the equity or 100% of the assets of the applicable NFP for a purchase price of $100 if, in the future, the New Mexico legislature adopts legislation that permits a NFP to (i) convert to a for-profit corporation and maintain its cannabis license or (ii) sell its assets (including its cannabis license) to a for-profit corporation. The aggregate closing consideration for the acquisitions was approximately (i) $27.7 million in cash, and (ii) $17.0 million in the form of an unsecured promissory note issued by Nuevo Holding, LLC to RGA, the principal amount of which is payable on February 8, 2025 with interest payable monthly at an annual interest rate of 5%. The Nuevo Purchasers issued an “earn-out” payment of $4.5 million in cash to RGA and William N. Ford (as Representative) based on the EBITDA of the acquired business for calendar year 2021.
| 10 |
On February 9, 2022, the Company acquired MCG, LLC and its four wholly-owned subsidiaries (collectively, “MCG”) pursuant to the terms of an Agreement and Plan of Merger, dated November 15, 2021, with Emerald Fields Merger Sub, LLC, a wholly-owned subsidiary of the Company, MCG, MCG’s owners, and Donald Douglas Burkhalter and James Gulbrandsen in their capacity as the Member Representatives, as amended on February 9, 2022.
On February 15, 2022, Double Brow, LLC (“Double Brow”) acquired substantially all of the operating assets of Brow 2, LLC (“Brow”) related to its indoor cannabis cultivation operations located in Denver, Colorado (other than assets expressly excluded) and assumed certain liabilities for contracts acquired pursuant to the terms of the Asset Purchase Agreement, dated August 20, 2021, among Double Brow, Brow, and Brian Welsh, as the owner of Brow.
On March 17, 2022, the Company announced that its Common Stock was approved for listing on the NEO, a tier one Canadian Stock exchange based in Toronto, Ontario. The Common Stock began trading on the NEO on March 23, 2022.
On May 31, 2022, the Company acquired substantially all of the operating assets of Urban Health & Wellness, Inc d/b/a Urban Dispensary (“Urban Dispensary”) pursuant to the terms of an Asset and Personal Goodwill Purchase Agreement, dated March 11, 2022, with Double Brow, Urban Dispensary, Productive Investments, LLC, and Patrick Johnson. Urban Dispensary operates an indoor cannabis cultivation facility and a single retail dispensary, each located in Denver, Colorado.
| 1. | Liquidity and Capital Resources |
During the quarter ended June 30, 2022 and year ended December 31, 2021, the Company primarily used revenues from its operations to fund its operations.
Cash and cash equivalents are carried at cost
and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original
maturity of three months or less as of the purchase date. The Company had $
The Company maintains its cash balances with financial institutions. At times, such cash may be more than the insured limit of $250,000. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on its cash and cash equivalents.
| 2. | Critical Accounting Policies and Estimates |
Management’s Representation of Interim Financial Statements
The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of the Company’s financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of December 31, 2021 and 2020, as presented in the Company’s Annual Report on Form 10-K filed on March 31, 2022 with the SEC.
| 11 |
Basis of Presentation
These accompanying financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC for interim financial statements. All intercompany accounts and transactions are eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.
Reclassifications
Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company’s net earnings and financial position.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.
The Company’s financial instruments include cash, accounts receivable, notes receivable, accounts payable and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt, including notes payable, approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs.
| 12 |
The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at June 30, 2022 and December 31, 2021, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Level 1 - Marketable Securities Available-for-Sale - Recurring | ||||||||
Marketable Securities at Fair Value on a Recurring Basis
Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc., a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange.
Fair Value of Financial Instruments
The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report.
The following table depicts the composition of our current and non-current accounts receivable as of June 30, 2022, and December 31, 2021:
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Accounts receivable - trade | $ | $ | ||||||
| Accounts receivable - related party | ||||||||
Accounts receivable - litigation, non-current | ||||||||
| Allowance for doubtful accounts | ( | ) | ( | ) | ||||
| Total accounts receivable | $ | $ | ||||||
The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required.
Notes Receivable
On March 12, 2021, the Company sold equipment
to Colorado Cannabis Company LLC (“Colorado Cannabis”). Colorado Cannabis is obligated to pay $215,000, payable in equal monthly
installments for 24 months commencing 30 days from the date of taking possession of the equipment pursuant to the Purchase and Sale Agreement,
dated January 29, 2021. As of June 30, 2022, the outstanding balance, including penalties for late payments, on the receivable from Colorado
Cannabis totaled $
| 13 |
Prepaid Expenses and Other Assets (Current and Non-Current)
Prepaid expenses and other assets as of June 30,
2022 and December 31, 2021 were $
Goodwill and Intangible Assets
Goodwill represents the future economic benefit
arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the
Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible
assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line
basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing
agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from
Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.
Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests.
The Company performed its annual fair value assessment as of December 31, 2021, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed as of June 30, 2022, that would indicate impairment.
Long-Lived Assets
The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.
| 14 |
The Company evaluated the recoverability of its long-lived assets on December 31, 2021, on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists.
Accounts Payable
Accounts payable as of June 30, 2022 and December
31, 2021 were $
Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities as of June
30, 2022 and December 31, 2021 were $
Revenue Recognition
The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of its results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer.
The Company has three main revenue streams: retail; wholesale; and other.
The Company’s retail and wholesale segment revenues are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.
The Company’s other segment revenue consists of other income related to, licensing and consulting services, facility design services, facility management services, the Company’s Three A Light™ publication, and corporate operations. Revenue is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded or earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.
Costs of Goods and Services Sold
Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services.
General and Administrative Expenses
General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s products and services.
| 15 |
Advertising and Marketing Costs
Advertising and marketing costs are expensed as
incurred and totaled $
The Company accounts for share-based payments pursuant to ASC 718, Stock Compensation and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model.
Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force 96-18 when stock or options are awarded for previous or current service without further recourse.
Share-based expense paid through direct stock grants is expensed as occurred. Since the Common Stock is publicly traded, the value is determined based on the number of shares of Common Stock issued and the trading value of the Common Stock on the date of the transaction.
On June 20, 2018, the Financial Accounting Standards Board (the “FASB”) issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance.
The Company recognized $ in expense for stock-based compensation from Common Stock options and Common Stock issued to employees, officers, and directors during the six months ended June 30, 2022, and $ in expenses for stock-based compensation from the issuance of Common Stock to employees, officers, directors and/or contractors during the six months ended June 30, 2021.
Income Taxes
ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.
| 16 |
The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business, and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.
As the Company operates in the cannabis industry, it is subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales, manufacturing or cultivation of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.
Right of Use Assets and Lease Liabilities
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The ASU requires lessees to recognize almost all leases on the balance sheet as a Right-of-Use (“ROU”) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard became effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under ASC 842. The Company elected the package of practical expedients permitted under the standard, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.
Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.
Operating leases are included in operating lease ROU assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets.
| 17 |
| 3. | Recent Accounting Pronouncements |
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements. Pronouncements that are not applicable to the Company or where it has been determined do not have a significant impact on the financial statements have been excluded herein.
In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.
| 4. | Property and Equipment |
Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Furniture and fixtures | $ | $ | ||||||
| Leasehold improvements | ||||||||
| Vehicles, machinery, and tools | ||||||||
| Land | ||||||||
| Servers & Office Equipment | ||||||||
| Software, servers and equipment | ||||||||
| Land Improvements | ||||||||
| Building | ||||||||
| PC & Peripherals | ||||||||
| Construction in process | ||||||||
| Total Asset Cost | $ | $ | ||||||
| Less: Accumulated depreciation | ( | ) | ( | ) | ||||
| Total property and equipment, net of depreciation | $ | $ | ||||||
Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.
| Furniture and fixtures | ||
| Leasehold improvements | ||
| Vehicles, machinery and tools | ||
| Land | ||
| Software, servers and equipment | ||
| Building | ||
Depreciation expense for the three and six
months ended June 30, 2022 was $
| 18 |
| 5. | Intangible Asset |
Intangible assets as of June 30, 2022 and December 31, 2021 were comprised of the following:
| June 30, 2022 | December 31, 2021 | |||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | |||||||||||||
| License Agreements | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Tradename | $ | ( | ) | ( | ) | |||||||||||
| Customer Relationships | $ | ( | ) | ( | ) | |||||||||||
| Non-compete | $ | ( | ) | ( | ) | |||||||||||
| Product License and Registration | $ | ( | ) | ( | ) | |||||||||||
| Trade Secret | $ | ( | ) | ( | ) | |||||||||||
| Total | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
Amortization expense for the three and six
months ended June 30, 2022 was $
| 6. | Derivative Liability |
Employee Common Stock
During the year ended December 31, 2019, the Company entered into employment agreements with certain key officers that contained contingent consideration provisions based upon the achievement of certain market condition milestones. The Company determined that each of these vesting conditions represented derivative instruments.
On January 8, 2019, the Company granted the right to receive shares of restricted Common Stock to an officer, which would have vested at such time that the Company’s stock price appreciated to $8.00 per share with defined minimum average daily trading volume thresholds. This right expired on January 8, 2022 and all expense had been recognized as of December 31, 2021.
On June 11, 2019, the Company granted the right to receive shares of restricted Common Stock to an officer, which would have vested at such time that the Company’s stock price appreciated to $8.00 per share with defined minimum average daily trading volume thresholds. This right expired January 8, 2022 and all expense had been recognized as of December 31, 2021.
The Company accounts for derivative instruments in accordance with the GAAP accounting guidance under ASC 815 Derivatives and Hedging Activities. The Company estimated the fair value of these derivatives at the respective balance sheet dates using the Black-Scholes option pricing model based upon the following inputs: (i) stock price on the date of grant ranging between $1.32 - $3.75, (ii) the contractual term of the derivative instrument ranging between 2.25 - 3 years, (iii) a risk-free interest rate ranging between 1.87% - 2.57% and (iv) an expected volatility of the price of the underlying Common Stock ranging between 145% - 158%.
The fair value of these derivative liabilities
is $
| 19 |
Investor Note
The Company issued Investor Notes in an aggregate
principal amount of $
| Balance as of January 1, 2021 | $ | |||
| Fair value of derivative liabilities on issuance date | ||||
| Gain on derivative liability | ( | ) | ||
| Balance as of December 31, 2021 | $ | |||
| Gain on derivative liability | ( | ) | ||
| Balance as of June 30, 2022 | $ |
The Company accounts for derivative instruments
in accordance with the GAAP accounting guidance under ASC 815 Derivatives and Hedging Activities. In accordance with GAAP, a contract
to issue a variable number of equity shares fails to meet the definition of equity and must instead be classified as a derivative liability
and measured at fair value with changes in fair value recognized in the consolidated statements of operations at each period-end. The
Company utilizes a Monte Carlo simulation in determining the appropriate fair value. The derivative liability will ultimately be converted
into the Company’s equity when the Investor Notes are converted or will be extinguished on the repayment of the Investor Notes.
The derivative liability will not result in the outlay of any additional cash by the Company. Upon initial recognition, the Company recorded
a derivative liability and debt discount of $
| 7. | Related Party Transactions |
Transactions Involving Former Directors, Executive Officers or Their Affiliated Entities
During the year ended December 31, 2019, the Company
made loans to MedPharm Holdings LLC (“MedPharm”) totaling $
| 20 |
Transactions with Entities Affiliated with Justin Dye
The Company has participated in several transaction involving Dye Capital, Dye Capital Cann Holdings, LLC (“Dye Cann I”) and Dye Capital Cann Holdings II, LLC (“Dye Cann II”). Justin Dye, the Company’s Chief Executive Officer, one of its directors, and the largest beneficial owner of Common Stock and Preferred Stock, controls Dye Capital and Dye Capital controls Dye Cann I and Dye Cann II. Dye Cann I is the largest holder of the Company’s outstanding Common Stock. Dye Cann II is a significant holder of our Preferred Stock. Mr. Dye has sole voting and dispositive power over the securities held by Dye Capital, Dye Cann I, and Dye Cann II.
The Company entered into a Securities Purchase
Agreement with Dye Cann I on June 5, 2019, (as amended, the “Dye Cann I SPA”) pursuant to which the Company agreed to sell
to Dye Cann I up to between 8,187,500 and 10,687,500 shares of Common Stock in several tranches at $2.00 per share and warrants to purchase
100% of the number of shares of Common Stock sold at a purchase price of $3.50 per share. At the initial closing on June 5, 2019, the
Company sold to Dye Cann I shares of Common Stock and warrants to purchase
The Company granted Dye Cann I certain demand and piggyback registration rights with respect to the shares of Common Stock sold under the Dye Cann I SPA and issuable upon exercise of the warrants sold under the Dye Cann I SPA. The Company also granted Dye Cann I the right to designate one or more individuals for election or appointment to the Company’s board of directors (the “Board”) and Board observer rights. Further, under the Dye Cann I SPA, until June 5, 2022, if the Company desires to pursue debt or equity financing, the Company must first give Dye Cann I an opportunity to provide a proposal to the Company with the terms upon which Dye Cann I would be willing to provide or secure such financing. If the Company does not accept Dye Cann I’s proposal, the Company may pursue such debt or equity financing from other sources but Dye Cann I has a right to participate in such financing to the extent required to enable Dye Cann I to maintain the percentage of Common Stock (on a fully-diluted basis) that it then owns, in the case of equity securities, or, in the case of debt, a pro rata portion of such debt based on the percentage of Common Stock (on a fully-diluted basis) that it then owns. The warrants granted to Dye Cann I pursuant to the Dye Cann I SPA expired on June 5, 2022.
The Company entered into a Securities
Purchase Agreement (as amended, the “Dye Cann II SPA”) with Dye Cann II on November 16, 2020 pursuant to which the
Company agreed to sell to Dye Cann II shares of Preferred Stock in one or more tranches at a price of $1,000 per share. The terms of
the Dye Cann II SPA are disclosed in the Company’s Current Report on Form 8-K filed on December 23, 2020. The Company and Dye
Cann II entered into an amendment to the Dye Cann II SPA on December 16, 2020, as described in the Company’s Current Report on
Form 8-K filed on December 23, 2020, a second amendment to the Dye Cann II SPA on February 3, 2021, as described in the
Company’s Form 8-K filed on February 9, 2021, and a third amendment to the Dye Cann II SPA on March 30, 2021, as described
under Item 9B of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company issued and sold to
Dye Cann II 7,700
shares of Preferred Stock on December 16, 2020, 1,450
shares of Preferred Stock on December 18, 2020, 1,300
shares of Series Preferred Stock on December 22, 2020, 3,100
shares of Preferred Stock on February 3, 2021, 1,300
shares of Preferred Stock on February 25, 2021, 2,500 shares of Preferred Stock on March 2, 2021 and 4,000
shares of Preferred Stock on March 30, 2021. As a result, the Company issued and sold an aggregate of
shares of Preferred Stock to Dye Cann II for aggregate gross proceeds of $
The Company granted Dye Cann II certain demand and piggyback registration rights with respect to the shares of Common Stock issuable upon conversion of the Preferred Stock under the Dye Cann II SPA. Further, the Company granted Dye Can II the right to designate one or more individuals for election or appointment to the Board and Board observer rights.
| 21 |
On December 16, 2020, the Company entered into
a Secured Convertible Note Purchase Agreement with Dye Capital and issued and sold to Dye Capital a Convertible Note and Security Agreement
in the principal amount of $
The Company previously reported the terms of the Preferred Stock in the Company’s Current Report on Form 8-K filed on December 23, 2020.
During the year ended December 31, 2021 the
Company recorded expenses of $
Transactions with Entities Affiliated with Jeffrey Cozad
On February 26, 2021, the Company entered into
a Securities Purchase Agreement (the “CRW SPA”) with CRW Cann Holdings, LLC (“CRW”) pursuant to which the Company
issued and sold shares of Preferred Stock to CRW at a price of $1,000 per share for aggregate gross proceeds of $
On December 7, 2021, the Company entered into
a Securities Purchase Agreement with Cozad Investments, L.P. pursuant to which the Company issued an Investor Note in the aggregate principal
amount of $
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Cozad as compensation for service on the Board. These shares are valued at $
| 22 |
Transactions with Entities Affiliated with Marc Rubin
On February 26, 2021, the Company entered into
the CRW SPA with CRW, of which Marc Rubin is a beneficial owner. On December 7, 2021, the Company entered into a Securities Purchase Agreement
with The Rubin Revocable Trust U/A/D 05/09/2011 pursuant to which the Company issued an Investor Note in the aggregate principal amount
of $
Transactions with Entities Affiliated with Brian Ruden
The Company has participated in several transactions involving entities owned or affiliated with Brian Ruden, one of its directors, a beneficial owner of more than 5% of the Common Stock and a beneficial owner of more than 5% of the Preferred Stock.
Between December 17, 2020 and March 2, 2021, the Company’s wholly-owned subsidiary SBUD LLC consummated the Star Buds Acquisition. The Company previously reported the terms of the applicable purchase agreements and related amendments in the Company’s Current Reports on Form 8-K filed June 8, 2020, September 21, 2020, December 22, 2020, and March 8, 2021.
The aggregate purchase price for the Star
Buds Acquisition was $
Mr. Ruden was a part-owner of each of the Star Buds companies that sold assets to SBUD LLC. Mr. Ruden owned 50% of Colorado Health Consultants LLC, 50% of Starbuds Aurora LLC, 50% of Starbuds Pueblo LLC, 50% of Starbuds Alameda LLC, 46% of SB Arapahoe LLC, 36% of Starbuds Commerce City LLC, 30% of Starbuds Louisville LLC, 25% of Starbuds Niwot LLC, 16.66% of Lucky Ticket LLC, 15% of KEW LLC, and 10% of LM MJC LLC.
In connection with acquiring the Star Buds assets for our Pueblo West, Niwot, Commerce City, Lakeside, Arapahoe and Aurora locations, SBUD LLC entered into a lease with each of 428 S. McCulloch LLC, Colorado Real Estate Holdings LLC, 5844 Ventures LLC, 5238 W 44th LLC, 14655 Arapahoe LLC and Montview Real Estate LLC, on substantially the same terms. Each of the leases is for an initial three-year term. The lease with 428 S. McCulloch LLC is for the Company’s Pueblo West Star Buds location and was effective on December 17, 2020. The lease with Colorado Real Estate Holdings LLC and 5844 Ventures LLC is for the Company’s Niwot and Commerce City Star Buds locations, respectively, and was effective on December 18, 2020. The lease with 5238 W 44th LLC is for the Company’s Lakeside Star Buds location and was effective on February 3, 2021. The lease with 14655 Arapahoe LLC and Montview Real Estate LLC is for the Company’s Arapahoe and Aurora locations, respectively, and was effective on March 2, 2021. The 428 S McCulloch LLC, 5844 Ventures LLC and 5238 W 44th LLC provides for a monthly rent payment of $5,000 with an aggregate of $180,000 during the initial term of the leases. The Colorado Real Estate Holdings LLC lease provides for a monthly rent payment of $6,779 with an aggregate of $244,044 during the initial term of the lease. The 14655 Arapahoe LLC lease provides for a monthly rent payment of $12,367 with an aggregate of $445,212 during the initial term of the lease. The Montview Real Estate LLC lease provides for a monthly rent of $6,250 with an aggregate of $225,000 during the initial term of the lease. During 2020, SBUD LLC made aggregate rent payments of $10,000. SBUD LLC made aggregate rent payments of $242,376 and $449,297 for the periods ending June 30, 2022 and December 31, 2021, respectively. In addition, SBUD LLC must pay each landlord’s expenses and disbursements incurred in connection with the ownership, operation, maintenance, repair and replacement of the premises. SBUD LLC has the option to renew each lease for two additional three-year terms with escalation. The Company has an option to purchase the premises at fair market value at any time during the lease term and also has a right of first refusal if the landlords desire to sell the premises to a third party.
| 23 |
On December 17, 2020, SBUD LLC entered into a Trademark License Agreement with Star Brands LLC under which Star Brands LLC licenses certain trademarks to SBUD LLC effective as of the closing of the entire Star Buds Acquisition. SBUD LLC has no payment obligation under this agreement. Mr. Ruden is a part-owner of Star Brands LLC.
In connection with the Star Buds Acquisition, the Company granted Mr. Ruden and Naser Joudeh the right designate individuals for election or appointment to the Board.
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Ruden as compensation for service on the Board. These shares are valued at $
Transactions with Jeff Garwood
On December 7, 2021, the Company entered into
a Securities Purchase Agreement with Jeff Garwood pursuant to which the Company issued an Investor Note in the aggregate principal amount
of $
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Garwood, as compensation for service on the Board. These shares are valued at $
Transactions with Pratap Mukharji
On December 7, 2021, the Company entered into
a Securities Purchase Agreement with Pratap Mukharji pursuant to which the Company issued an Investor Note in the aggregate principal
amount of $
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Mukharji as compensation for service on the Board. These shares are valued at $
Transactions with Paul Montalbano
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Montalbano as compensation for service on the Board. These shares are valued at $
Transactions with Jonathan Berger
On May 4, 2022, and June 14, 2022, the
Company issued
shares of Common Stock and
shares of Common Stock, respectively, to Mr. Berger as compensation for service on the Board. These shares are valued at $
Transactions with Salim Wahdan
On June 14, 2022, and June 24, 2022, the Company
issued shares of Common Stock and shares of Common Stock, respectively, to Mr. Wahdan as compensation for service on the
Board. These shares are valued at $
| 24 |
| 8. | Goodwill Accounting |
The Company accounts for acquisitions in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase.
On June 3, 2017, the Company issued an aggregate
of shares of its Common Stock for 100% ownership of both Success Nutrients and Pono Publications. The Company utilized purchase
price accounting to value assets acquired, which values such assets at approximately fair market value. The purchase price accounting
resulted in $
On July 21, 2017, the Company issued
shares of its Common Stock for 100% ownership of Denver Consulting Group. The Company utilized purchase price accounting to value assets
acquired, which values such assets at approximately fair market value. The purchase price accounting resulted in $
On September 17, 2018, the Company acquired The
Big Tomato. The Company issued an aggregate of shares of its Common Stock for 100% ownership of Big Tomato. The Company utilized
purchase price accounting to value assets acquired, which values such assets at approximately fair market value. The purchase price accounting
resulted in the Company valuing the investment as $
On April 20, 2020, the Company acquired Mesa Organics.
The aggregate purchase price after working capital adjustments was $
From December 2020 through March 2021, the Company
acquired thirteen Star Buds dispensaries and one cultivation facility. The aggregate purchase price was $118,000,000. The Company utilized
purchase price accounting to value assets acquired, which values such assets at approximately fair market value. The purchase price accounting
resulted in the Company valuing the investment as $
On July 21, 2021, the Company acquired the assets
of Southern Colorado Growers. The Company utilized purchase price accounting to value assets acquired, which values such assets at approximately
fair market value. The purchase price accounting resulted in $
On December 21, 2021, the Company acquired the
assets of Smoking Gun. The Company utilized purchase price accounting to value assets acquired, which values such assets at
approximately fair market value. The purchase price accounting resulted in $
On January 26, 2022, the Company acquired the
assets of Drift. The Company utilized purchase price accounting to value assets acquired, which values such assets at approximately fair
market value. The purchase price accounting resulted in $
On February 8, 2022, the Company acquired the
assets of RGA and 100% of the equity of Elemental. The Company utilized purchase price accounting to value assets acquired, which values
such assets at approximately fair market value. The purchase price accounting resulted in $
| 25 |
On February 9, 2022, the Company acquired MCG.
The Company utilized purchase price accounting to value assets acquired, which values such assets at approximately fair market value.
The purchase price accounting resulted in $
On February 15, 2022, the Company acquired the
assets of Brow. The Company utilized purchase price accounting to value assets acquired, which values such assets at approximately fair
market value. The purchase price accounting resulted in $
On May 31, 2022, the Company acquired the assets
of Urban Dispensary. The Company utilized purchase price accounting to value assets acquired, which values such assets at approximately
fair market value. The purchase price accounting resulted in $
As of June 30, 2022, the Company had $
| 9. | Business Combination |
During the three and six months ended June 30, 2022, the Company acquired cannabis brands and other assets of Drift, RGA, MCG, Brow, Urban Dispensary, and 100% of the equity of Elemental.
These transactions were accounted for as a business combination in accordance with ASC 805, Business Combinations (“ASC 805”). In consideration of the sale and transfer of the acquired assets the Company paid as follows:
| Nuevo Holding LLC | Emerald Fields Merger Sub, LLC | Other Acquisitions | ||||||||||
| Cash | $ | $ | $ | |||||||||
| Seller notes | ||||||||||||
| Common stock | ||||||||||||
| Total purchase price | $ | $ | $ | |||||||||
| 26 |
As of June 30, 2022, the Company’s allocation of purchase price is as follows:
| Description | Nuevo Holding LLC | Emerald Fields Merger Sub, LLC | Other Acquisitions | |||||||||
| Assets acquired: | ||||||||||||
| Cash | $ | $ | $ | |||||||||
| Accounts receivable | ||||||||||||
| Other assets | ||||||||||||
| Inventory | ||||||||||||
| Fixed assets | ||||||||||||
| Other long term assets | ||||||||||||
| Intangible assets | ||||||||||||
| Goodwill | ||||||||||||
| Total Assets acquired | $ | $ | $ | |||||||||
| Liabilities and Equity assumed: | ||||||||||||
| Accounts payable | $ | $ | $ | |||||||||
| Accrued liabilities | ||||||||||||
| Total Liabilities and Equity assumed | ||||||||||||
| Estimated fair value of net assets acquired | $ | $ | $ | |||||||||
| 10. | Inventory |
As of June 30, 2022, and December 31, 2021,
respectively, the Company had $
| 11. | Debt |
Term Loan — On February 26,
2021, the Company entered into a Loan Agreement with SHWZ Altmore, LLC (“Altmore”), as lender, and GGG Partners LLC, as collateral agent. Upon
execution of the Loan Agreement, the Company received $
Under the terms of the loan, the Company must comply with certain restrictions. These include customary events of default and various financial covenants including, maintaining (i) a consolidated fixed charge coverage ratio of at least 1.3 at the end of each fiscal quarter beginning in the first quarter of 2022, and (ii) a minimum of $3,000,000 in a deposit account in which the lender has a security interest. As of June 30, 2022, the Company was in compliance with the requirements described above.
| 27 |
Seller Notes — As part of the Star
Buds Acquisition, the Company entered into a deferred payment arrangement with the sellers in an aggregate amount of $
As part of the acquisition under the Nuevo Purchase
Agreement, the company entered into a deferred payment arrangement with the sellers in an aggregate amount of $
Investor Notes – On December 3, 2021,
the Company and the Subsidiary Guarantors entered into a Securities Purchase Agreement with the Note Investors pursuant to which the Company
agreed to issue and sell to the Note Investors Investor Notes in a private placement. On December 7, 2021, the Company consummated the
private placement and issued and sold the Investor Notes pursuant to the Indenture. The Company received net proceeds of approximately
$
The Indenture includes customary affirmative and negative covenants, including limitations on liens, additional indebtedness, repurchases and redemptions of any equity interest in the Company or any Subsidiary Guarantor (as defined in the Indenture), certain investments, and dividends and other restricted payments, and customary events of default. Starting on December 7, 2022, the Company must maintain a Consolidated Fixed Charge Coverage Ratio (as defined in the Indenture) of no less than 1.30 to 1.00 as of the last day of each quarter, and the Company and the Subsidiary Guarantors are required to have at least $10,000,000 in cash (in aggregate) on the last day of each quarter in deposit accounts for which the collateral agent has a perfected security interest in. The Company and the Subsidiary Guarantors are restricted from making certain payments, including but not limited to (i) payment of dividends, (ii) repurchase, redemption, retire, or otherwise acquire any equity interest, option, or warrant of the Company or any Subsidiary Guarantor, and (iii) payment to any equity holder of the Company or a Subsidiary Guarantor for services provided pursuant to management, consulting, or other service agreement (the “Restricted Payments”) but the Company may declare and pay dividends if payable solely in its own equity, or, in the case of the Subsidiary Guarantors, amounts payable to such subsidiaries with respect to its applicable equity ownership. Provided the Company is not in default under the terms of the Indenture, the Company may make Restricted Payments not otherwise permitted thereunder (a) in an amount not to exceed $500,000 until discharge of the Indenture, or (b) after December 7, 2024, so long as the Company’s Consolidated Leverage Ratio (as defined in the Indenture) is between 1.00 and 2.25 for the applicable reference period at the time of the Restricted Payment after giving pro forma effect thereto.
The Indenture contains restrictions and
limitations on the Company’s ability to incur additional debt and grant liens on its assets. The Company and its Subsidiary
Guarantors are not permitted to incur additional debt or issue Disqualified Equity Interests (as defined in the Indenture) unless
the Company’s Consolidated Leverage Ratio is between 1.00 and 2.25 after giving pro forma effect thereto. In addition, the
Company is not permitted to grant a senior lien on its assets (excluding acquisition target assets that are identified in the
Indenture) to secure indebtedness unless and until (a) at least $
| 28 |
The following tables sets forth our indebtedness as of June 30, 2022 and December 31, 2021, respectively, and future obligations:
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Term loan dated February 26, 2021, in the original amount of $ | $ | $ | ||||||
| Seller notes dated December 17, 2020 in the original amount of $ | ||||||||
| Convertible note dated December 3, 2021, in the original amount of $ | ||||||||
| Seller note dated February 7, 2022 in the original amount of $ | ||||||||
| Less: unamortized debt issuance costs | ( | ) | ( | ) | ||||
| Less: unamortized debt discount | ( | ) | ( | ) | ||||
| Total long term debt | ||||||||
| Less: current portion of long term debt | ||||||||
| Long term debt and unamortized debt issuance costs | $ | $ | ||||||
| Principal Payments | Unamortized Debt Issuance Costs | Unamortized Debt Discount | Total Long Term Debt | |||||||||||||
| 2022 | $ | $ | $ | ( | ) | |||||||||||
| 2023 | ( | ) | ||||||||||||||
| 2024 | ( | ) | ||||||||||||||
| 2025 | ||||||||||||||||
| 2026 | ||||||||||||||||
| Thereafter | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| 29 |
| 12. | Leases |
Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Leases with a term greater than one year are recognized on the balance sheet at the time of lease commencement or modification of a Right of Use (“ROU”) operating lease asset and a lease liability, initially measured at the present value of the lease payments. Lease costs are recognized in the income statement over the lease term on a straight-line basis. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.
The Company's leases consist of real estate leases for office, retail, cultivation, and manufacturing facilities. The Company elected to combine the lease and related non-lease components for its operating leases.
The Company’s operating leases include options to extend or terminate the lease, which are not included in the determination of the ROU asset or lease liability unless reasonably certain to be exercised. The Company's operating leases have remaining lease terms of less than two years. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
As the Company's leases do not provide an implicit
rate, we used an incremental borrowing rate based on the information available at the lease commencement date in determining the present
value of lease payments. The discount rate used in the computations ranged between
Balance Sheet Classification of Operating Lease Assets and Liabilities
| Balance Sheet Line | June 30, 2022 | |||||
| Asset | ||||||
| Operating lease right of use assets | Noncurrent assets | $ | ||||
| Liabilities | ||||||
| Lease liabilities | Current Liabilities | $ | ||||
| Lease liabilities | Noncurrent liabilities | |||||
Maturities of Lease Liabilities
Maturities of lease liabilities as of June 30, 2022 are as follows:
| 2022 fiscal year | $ | |||
| Less: Interest | ||||
| Present value of lease liabilities | $ |
The following table presents the Company’s future minimum lease obligation under ASC 842 as of June 30, 2022:
| 2022 fiscal year | $ | |||
| 2023 fiscal year | ||||
| 2024 fiscal year | ||||
| 2025 fiscal year | ||||
| 2026 fiscal year | ||||
| Thereafter | ||||
| Total | $ |
| 30 |
| 13. | Commitments and Contingencies |
Definitive Agreement to Invest in Colorado-Based Mission Holdings.
Effective as of July 13, 2022, the Company entered into a strategic relationship with Mission Holdings US, Inc. (“Mission Holdings”), an entity affiliated with MCG, by purchasing a non-controlling equity interest in Mission Holdings. Mission Holdings offers various products and brands, including proprietary cannabis infused gummies and premium flower for medical and recreational sale in Colorado and California. The Company has the right to acquire 100% of the equity interest in Mission on or after the three-year anniversary of the investment.
| 14. | Stockholders’ Equity |
The Company is authorized to issue two classes of stock, preferred stock and Common Stock.
Preferred Stock
The number of shares of preferred stock authorized is , par value $ per share. The preferred stock may be divided into such number or series as the Board may determine. The Board is authorized to determine and alter the rights, preferences, privileges and restrictions granted and imposed upon any wholly unissued series of preferred stock, and to fix the number and designation of shares of any series of preferred stock. The Board, within limits and restrictions stated in any resolution of the Board, originally fixing the number of shares constituting any series may increase or decrease, but not below the number of such series then outstanding, the shares of any subsequent series.
The Company had
shares of Preferred Stock issued and in escrow as of June 30, 2022 and December 31, 2021. Among other terms, each share of Preferred Stock (i) earns an
annual dividend of 8% on the “preference amount,” which initially is equal to the $1,000 per-share purchase price and
subject to increase, by having such dividends automatically accrete to, and increase, the outstanding preference amount, (ii) is
entitled to a liquidation preference under certain circumstances, (iii) is convertible into shares of Common Stock by dividing the
preference amount by $1.20 per share under certain circumstances, and (iv) is subject to a redemption right or obligation under
certain circumstances. Preferred dividends were $
| 31 |
Common Stock
The Company is authorized to issue shares of Common Stock, par value $ per share. The Company had 55,995,681 shares of Common Stock issued, 54,446,575 shares of Common Stock outstanding, shares of Common Stock in treasury, and 662,647 shares of Common Stock in escrow as of June 30, 2022, and shares of Common Stock issued, shares of Common Stock outstanding, shares of Common Stock in treasury, and 221,400 shares of Common Stock in escrow as of December 31, 2021.
Common Stock Issued as Compensation to Employees, Officers, and Directors
For the year ended December 31, 2021, the Company issued shares of Common Stock valued at $ to employees and directors as compensation.
For the six months ended June 30, 2022, the Company issued shares of Common Stock valued at $ as compensation to directors.
Common and Preferred Stock Issued as Payment for Acquisitions
On April 20, 2020, the Company issued
shares of Common Stock valued at $
The Company issued shares of Preferred Stock
in connection with the Star Buds Acquisition to each relevant selling party as follows: (i) on December 17, 2020 the Company issued
shares of Preferred Stock valued at $
On July 21, 2021, the Company issued
shares of Common Stock valued at $
On December 21, 2021, the Company issued
shares of Common Stock valued at $
On January 26, 2022, the Company issued
shares of Common Stock valued at $
On February 9, 2022, the Company issued
shares of Common Stock valued at $
On May 31, 2022, the Company issued shares of Common Stock valued at $
| 32 |
Warrants
The Company accounts for Common Stock purchase warrants in accordance with ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity. The Company estimates the fair value of warrants at date of grant using the Black-Scholes option pricing model. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants, and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.
For the year ended December 31, 2021, the Company issued warrants to purchase an aggregate of shares of Common Stock as consideration for the Star Buds Acquisition. These warrants have an exercise price of $per share and expiration dates five years from the dates of issuance. In addition, the Company issued a warrant to purchase an aggregate of shares of Common Stock to Altmore in connection with entering into a loan agreement. This warrant has an exercise price of $per share and expires five years from the date of issuance. The Company estimated the fair value of these warrants at date of grant using the Black-Scholes option pricing model using the following inputs: (i) stock price on the date of grant of $and $, respectively, (ii) the contractual term of the warrant of five years, (iii) a risk-free interest rate ranging between % - % and (iv) an expected volatility of the price of the underlying Common Stock ranging between % - %. As of June 30, 2022, 1,500,000 warrants issued to Dye Cann I and 900,000 warrants issued to accredited investors in 2019 expired. No new warrants were issued as of June 30, 2022.
The following table reflects the change in Common Stock purchase warrants for the period ended June 30, 2022:
| Number of shares | ||||
| Balance as of December 31, 2021 | ||||
| Warrants exercised | ||||
| Warrants forfeited/expired | ( | ) | ||
| Warrants issued | ||||
| Balance as of June 30, 2022 | ||||
Conversion of Preferred Stock to Common Stock
On December 20, 2021, a holder of Preferred Stock converted shares of Preferred Stock into shares of Common Stock.
| 15. | Segment Information |
The Company has three identifiable segments as of June 30, 2022; (i) retail, (ii) wholesale and (iii) and other. The retail segment represents our dispensaries which sell merchandise directly to customers via retail locations and e-commerce portals. The wholesale segment represents our manufacturing, cultivation, and wholesale business which sells merchandise to customers via e-commerce portals, a retail location, and a manufacturing facility. The other segment derives its revenue from licensing and consulting agreements with cannabis related entities, in addition to fees from seminars and expense reimbursements included in other revenue on the Company’s financial statements.
| 33 |
The following information represents segment activity for the three months ended June 30, 2022:
| Retail | Wholesale | Other | Total | |||||||||||||
| Revenues | ||||||||||||||||
| Cost of goods and services | ( | ) | ( | ) | ( | ) | ||||||||||
| Gross profit | ||||||||||||||||
| Intangible assets amortization | ||||||||||||||||
| Depreciation | ||||||||||||||||
| Net income (loss) | ||||||||||||||||
| Segment assets | ||||||||||||||||
The following information represents segment activity for the six months ended June 30, 2022:
| Retail | Wholesale | Other | Total | |||||||||||||
| Revenues | ||||||||||||||||
| Cost of goods and services | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gross profit | ||||||||||||||||
| Intangible assets amortization | ||||||||||||||||
| Depreciation | ||||||||||||||||
| Net income (loss) | ( | ) | ( | ) | ||||||||||||
| Segment assets | ||||||||||||||||
Segment assets from Other mainly related to cash from the Investor Notes.
| 16. | Tax Provision |
The following table summarizes the Company’s income tax expense and effective tax rates for three and six months ended June 30, 2022 and June 30, 2021:
| Three Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Income (loss) before income taxes | $ | $ | ||||||
| Income tax expense | ||||||||
| Effective tax rate | ||||||||
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Income (loss) before income taxes | $ | $ | ||||||
| Income tax expense | ||||||||
| Effective tax rate | ||||||||
| 34 |
The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. We believe that, at this time, the use of this discrete method is more appropriate than the annual effective tax rate method as the estimated annual effective tax rate method is not reliable due to the high degree of uncertainty in estimating annual pre-tax income due to the early growth stage of the business.
Due to its cannabis operations, the Company is subject to the limitations of IRC Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.
The effective tax rate for the three months and six months ended June 30, 2022 varies from the three months and six months ended June 30, 2021 primarily due to the change in nondeductible expenses as a proportion of total expenses in the current year. The Company incurs expenses that are not deductible dur to IRC Section 280E limitations which results in significant income tax expense.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company's valuation allowance represents the amount of tax benefits that are likely to not be realized. Management assesses the need for a valuation allowance each period and continues to have a full valuation allowance on its deferred tax assets as of June 30, 2022.
The Federal statute of limitation remains open for the 2017 tax year to present. The state statute of limitation remains open for the 2016 tax year to present.
| 17. | Earnings per share (Basic and Dilutive) |
The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted Earnings Per Share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to Common Stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. These potential dilutive shares include 6,185,750 of vested stock options, 14,618,750 stock purchase warrants, and 86,994 shares of Preferred Stock. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
The following is a reconciliation of the numerator and denominator used in the basic and diluted EPS calculations for the three and six months ended June 30, 2022 and 2021.
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net income (loss) | $ | 33,840,983 | $ | 4,370,040 | $ | 7,062,281 | $ | 720,531 | ||||||||
| Less: Accumulated preferred stock dividends for the period | (1,766,575 | ) | – | (3,510,019 | ) | – | ||||||||||
| Net income (loss) attributable to common stockholders | $ | 32,074,408 | $ | 4,370,040 | $ | 3,552,262 | $ | 720,531 | ||||||||
| Denominator: | ||||||||||||||||
| Weighted-average shares of common stock | 49,178,494 | 42,332,144 | 49,178,494 | 42,286,168 | ||||||||||||
| Basic earnings per share | $ | 0.65 | $ | 0.10 | $ | 0.07 | $ | 0.02 | ||||||||
| Numerator: | ||||||||||||||||
| Net income (loss) attributable to common stockholders - dilutive | $ | 32,074,408 | $ | 4,370,040 | $ | 3,552,262 | $ | 720,531 | ||||||||
| Denominator: | ||||||||||||||||
| Weighted-average shares of common stock | 49,178,494 | 42,332,144 | 49,178,494 | 42,286,168 | ||||||||||||
| Dilutive effect of warrants | 1,483,994 | 2,558,877 | 1,483,994 | 2,558,877 | ||||||||||||
| Dilutive effect of options | 1,114,415 | 9,084,500 | 1,114,415 | 9,041,682 | ||||||||||||
| Dilutive effect of preferred stock | 81,704,765 | – | 81,704,765 | – | ||||||||||||
| Diluted weighted-average shares of common stock | 133,481,667 | 53,975,521 | 133,481,667 | 53,886,727 | ||||||||||||
| Diluted earnings per share | $ | 0.24 | $ | 0.08 | $ | 0.03 | $ | 0.01 | ||||||||
Basic net loss per share attributable to common stockholders is computed by dividing reported net loss attributable to common stockholders by the weighted average number of common shares outstanding for the reported period. Note that for purposes of basic loss per share calculation, shares of Preferred Stock are excluded from the calculation as of December 31, 2021, as the inclusion of the common share equivalents would be anti-dilutive. As the Company incurred a loss from operations in 2020, shares of Common Stock issuable pursuant to the equity awards were excluded from the computation of diluted net loss per share in the accompanying consolidated statement of operations, as their effect is anti-dilutive.
| 18. | Subsequent Events |
In accordance with FASB ASC 855-10, Subsequent Events, the Company has analyzed its operations subsequent to June 30, 2022 to the date these consolidated financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these consolidated financial statements.
Effective as of July 13, 2022, the Company entered into a strategic relationship with Mission Holdings US, Inc. (“Mission Holdings”), an entity affiliated with MCG, by purchasing a non-controlling equity interest in Mission Holdings. Mission Holdings offers various products and brands, including proprietary cannabis infused gummies and premium flower for medical and recreational sale in Colorado and California. The Company has the right to acquire 100% of the equity interest in Mission on or after the three-year anniversary of the investment.
| 35 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our unaudited consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC. In addition to our historical unaudited condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A, “Risk Factors.” See also, “CAUTIONARY NOTE ABOUT FORWARD-LOOKING INFORMATION.”
Overview of the Company
Established in 2014 and headquartered in Denver, Colorado, Medicine Man Technologies, Inc., is a cannabis consumer packaged goods company and retailer. The Company’s focus is on building the premier, vertically integrated cannabis company by taking operating systems to other states where it can develop a differentiated leadership position. The Company is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company currently operates in Colorado and New Mexico.
Results of Operations – Consolidated
The following table sets forth the Company’s selected consolidated financial results for the periods, and as of the dates, indicated. The (i) consolidated statements of operations for the three and six months ended June 30, 2022 and June 30, 2021 and (ii) consolidated balance sheet as of June 30, 2022 and December 31, 2021 have been derived from and should be read in conjunction with the consolidated financial statements and accompanying notes presented in this report.
The Company’s consolidated financial statements have been prepared in accordance with GAAP and on a going-concern basis that contemplates continuity of operations and realization of assets and liquidation of liabilities in ordinary course of business.
Revenue segments
The Company has consolidated financial statements across its operating businesses with operating segments of retail, wholesale and other. The Company also accounts for revenue by state within the operating segments of retail, wholesale, and other for the State of Colorado and the State of New Mexico, which are reported below.
Revenue of Operation by Segment
| For the Three Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Retail | $ | 38,138,799 | $ | 21,525,816 | $ | 16,612,983 | 77% | |||||||||
| Wholesale | 6,080,843 | 9,186,181 | $ | (3,105,338 | ) | -34% | ||||||||||
| Other | 43,750 | 16,844 | $ | 26,906 | 160% | |||||||||||
| Total revenue | $ | 44,263,392 | $ | 30,728,841 | $ | 13,534,551 | 44% | |||||||||
| For the Six Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Retail | $ | 64,664,515 | $ | 33,342,016 | $ | 31,322,499 | 94% | |||||||||
| Wholesale | 11,288,231 | 16,632,445 | $ | (5,344,214 | ) | -32% | ||||||||||
| Other | 88,200 | 94,494 | $ | (6,294 | ) | -7% | ||||||||||
| Total revenue | $ | 76,040,946 | $ | 50,068,955 | $ | 25,971,991 | 52% | |||||||||
| 36 |
Revenue of Operation by State
| For the Three Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Colorado | $ | 32,828,362 | $ | 30,728,841 | $ | 2,099,521 | 7% | |||||||||
| New Mexico | 11,435,030 | – | $ | 11,435,030 | *** | |||||||||||
| Total revenue | $ | 44,263,392 | $ | 30,728,841 | $ | 13,534,551 | 44% | |||||||||
| For the Six Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Colorado | $ | 60,033,765 | $ | 50,068,955 | $ | 9,964,810 | 20% | |||||||||
| New Mexico | 16,007,181 | – | $ | 16,007,181 | *** | |||||||||||
| Total revenue | $ | 76,040,946 | $ | 50,068,955 | $ | 25,971,991 | 52% | |||||||||
Revenues for Colorado and New Mexico for the three months ended June 30, 2022, totaled $32,828,362 and $11,435,030, respectively. Revenue for Colorado for the three months ended June 30, 2022 increased by $2,099,521, or 7% compared to the prior period. Revenues for New Mexico for the three months ended June 30, 2022 increased $11,435,030 compared to the prior period, as the Company purchased the New Mexico business in the first quarter of 2022. For the three months ended June 30, 2022, Colorado and New Mexico represented 74% and 26%, respectively, of the Company’s total revenue.
Revenues for Colorado and New Mexico for the six months ended June 30, 2022, totaled $60,033,765 and $16,007,181, respectively. Revenue for Colorado for the six months ended June 30, 2022 increased by $9,964,810, or 20% compared to the prior period. Revenues for New Mexico for the six months ended June 30, 2022 increased $16,007,181 compared to the prior period, as the Company purchased the New Mexico business in the first quarter of 2022. For the six months ended June 30, 2022, Colorado and New Mexico represented 79% and 21%, respectively, of the Company’s total revenue.
For the Three Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Total revenue | $ | 44,263,392 | $ | 30,728,841 | $ | 13,534,551 | 44% | |||||||||
| Total cost of goods and services | 19,106,944 | 15,826,341 | (3,280,603 | ) | -21% | |||||||||||
| Gross profit | 25,156,448 | 14,902,500 | 10,253,948 | 69% | ||||||||||||
| Total operating expenses | 16,120,798 | 10,461,584 | (5,659,214 | ) | -54% | |||||||||||
| Income (loss) from operations | 9,035,650 | 4,440,916 | 4,594,734 | 103% | ||||||||||||
| Total other income (expense) | 29,211,295 | 157,598 | 29,053,697 | 18435% | ||||||||||||
| Provision for income taxes (benefit) | 4,405,962 | 228,474 | (4,177,488 | ) | -1828% | |||||||||||
| Net income (loss) | $ | 33,840,983 | $ | 4,370,040 | $ | 29,470,943 | 674% | |||||||||
| Earnings (loss) per share attributable to common shareholders - basic | $ | 0.65 | $ | 0.10 | $ | 0.55 | 550% | |||||||||
| Earnings (loss) per share attributable to common shareholders - diluted | $ | 0.24 | $ | 0.08 | $ | 0.16 | 200% | |||||||||
| Weighted average number of shares outstanding - basic | 49,178,494 | 42,332,144 | ||||||||||||||
| Weighted average number of shares outstanding - diluted | 133,481,667 | 53,975,521 | ||||||||||||||
| 37 |
Quarter Ended June 30, 2022 Compared to the Quarter Ended June 30, 2021
Revenue
Revenues for the three months ended June 30, 2022 totaled $44,263,392, including (i) retail sales of $38,138,799 (ii) wholesale sales of $6,080,843 and (iii) other operating revenues of $43,750, compared to revenues of $30,728,841, including (i) retail sales of $21,525,816, (ii) wholesale of $9,186,181, and (iii) other operating revenues of $16,844 during the three months ended June 30, 2021, representing an increase of $13,534,551 or 44%. This increase was due to increased sales of our products as well as execution of our growth through acquisition initiatives. In the second quarter of 2022, the Company acquired one additional retail dispensary, which generated additional retail revenue. Additionally, recreational marijuana sales became legal in New Mexico in April 2022, which increased sales volume and revenues in New Mexico. Wholesale revenues in Colorado decreased due to increased cultivation capacity in the state resulting in an over-supply of wholesale cannabis materials.
Cost of Goods and Services
Cost of goods and services for the three months ended June 30, 2022 totaled $19,106,944 compared to cost of goods and services of $15,826,341 during the three months ended June 30, 2021, representing an increase of $3,280,603 or 21%. The increase in cost of goods and services is driven by the increase in revenues, however not at the same rate. During the three months ended June 30, 2022, the Company experienced a reduction in costs driven by vertical integration and third-party price negotiations.
Operating Expenses
Operating expenses for the three months ended June 30, 2022 totaled $16,120,798, compared to operating expenses of $10,461,584 during the three months ended June 30, 2021, representing an increase of $5,659,214 or 54%. This increase is due to increased selling, general and administrative expenses, professional service fees, salaries, benefits and related employment costs mainly driven by growth from acquisitions.
Other Income (Expense), Net
Other expense, net for the three months ended June 30, 2022 totaled $29,211,295 compared to $157,598 during the three months ended June 30, 2021, representing an increase in income of $29,053,697 or 18,435%. The increase in other income is due to the revaluation of the derivative liability related to the Investor Notes, offset by higher interest payments.
Net Income (Loss)
As a result of the factors discussed above, we generated net income for the three months ended June 30, 2022 of $33,840,983, compared to net income of $4,370,040 for the three months ended June 30, 2021.
| 38 |
For the Six Months Ended June 30, | 2022 vs 2021 | |||||||||||||||
| 2022 | 2021 | $ | % | |||||||||||||
| Total revenue | $ | 76,040,946 | $ | 50,068,955 | $ | 25,971,991 | 52% | |||||||||
| Total cost of goods and services | 39,946,995 | 27,913,451 | (12,033,544 | ) | -43% | |||||||||||
| Gross profit | 36,093,951 | 22,155,504 | 13,938,447 | 63% | ||||||||||||
| Total operating expenses | 31,848,841 | 19,199,495 | (12,649,346 | ) | -66% | |||||||||||
| Income (loss) from operations | 4,245,110 | 2,956,009 | 1,289,101 | 44% | ||||||||||||
| Total other income (expense) | 8,483,027 | (1,550,390 | ) | 10,033,417 | -647% | |||||||||||
| Provision for income taxes (benefit) | 5,665,856 | 685,088 | (4,980,768 | ) | -727% | |||||||||||
| Net income (loss) | $ | 7,062,281 | $ | 720,531 | $ | 6,341,750 | 880% | |||||||||
| Earnings (loss) per share attributable to common shareholders - basic | $ | 0.07 | $ | 0.02 | $ | 0.05 | 250% | |||||||||
| Earnings (loss) per share attributable to common shareholders - diluted | $ | 0.03 | $ | 0.01 | $ | 0.02 | 200% | |||||||||
| Weighted average number of shares outstanding - basic | 49,178,494 | 42,286,168 | ||||||||||||||
| Weighted average number of shares outstanding - diluted | 133,481,667 | 53,886,727 | ||||||||||||||
Year to Date June 30, 2022 Compared to the Year to Date June 30, 2021
Revenue
Revenues for the six months ended June 30, 2022 totaled $76,040,946, including (i) retail sales of $64,664,515 (ii) wholesale sales of $11,288,231 and (iii) other operating revenues of $88,200, compared to revenues of $50,068,955, including (i) retail sales of $33,342,016, (ii) wholesale of $16,632,445, and (iii) other operating revenues of $94,494 during the six months ended June 30, 2021, representing an increase of $25,971,991 or 52%. This increase was due to increased sales of our products as well as execution of our growth through acquisitions initiatives. The Company acquired fifteen additional retail dispensary during the six months ended June 30, 2022, which increased retail revenue during such periods. New Mexico legalized recreational cannabis sales in the second quarter of 2022, which caused revenues in New Mexico to increase. Wholesale revenue decreased due to wholesale distillate pricing pressure, increased competitors in the cannabis cultivation market and over-supply of wholesale cannabis materials.
Cost of Goods and Services
Cost of goods and services for the six months ended June 30, 2022 totaled $39,946,995 compared to cost of goods and services of $27,913,451 during the six months ended June 30, 2021, representing an increase of $12,033,544 or 43%. The increase in cost of goods and services is driven by the increase in revenue, however not at the same rate. During the six months ended June 30, 2022, the Company experienced a reduction in costs driven by vertical integration and third-party price negotiations.
Operating Expenses
Operating expenses for the six months ended June 30, 2022 totaled $31,848,841, compared to operating expenses of $19,199,495 during the six months ended June 30, 2021, representing an increase of $12,649,346 or 66%. This increase is due to increased selling, general and administrative expenses, professional service fees, salaries, benefits and related employment costs mainly driven by growth from acquisitions.
| 39 |
Other Income (Expense), Net
Other income, net for the six months ended June 30, 2022 totaled $8,483,027 compared to other expenses, net, of $1,550,390 during the three months ended June 30, 2021, representing an increase in income of $10,033,417 or 647%. The increase in other income, net is due to the revaluation of the derivative liability related to the Investor Notes, offset by higher interest payments.
Net Income (Loss)
As a result of the factors discussed above, we generated net income for the six months ended June 30, 2022 of $7,062,281, compared to net income of $720,531 for the six months ended June 30, 2021.
Drivers of Results of Operations & Key Performance Indicators
Revenue
The Company derives its revenue from three revenue streams: Retail which sells finished goods sourced internally and externally to the end consumer in retail stores; Wholesale which is the cultivation of flower and biomass sold internally and externally and the manufacturing of biomass into distillate for integration into externally developed products, such as edibles and internally developed products such as vapes and cartridges under the Purplebee’s brand; Other which includes other income and expenses, such as, licensing and consulting services, facility design services, facility management services, the Company’s Three A Light™ publication, and corporate operations.
Gross Profit
Gross profit is revenue less cost of goods sold. Cost of goods sold includes costs directly attributable to product sales and includes amounts paid for finished goods such as flower, edibles, and concentrates, as well as manufacturing and cultivation labor, packaging, supplies and overhead such as rent, utilities and other related costs. Cannabis costs are affected by market supply. Gross margin measures our gross profit as a percentage of revenue.
Total Operating Expenses
Total operating expenses other than the costs of goods sold consists of selling costs to support customer relations, marketing and branding activities. It also includes an investment in the corporate infrastructure required to support the Company’s ongoing business.
Adjusted EBITDA
Adjusted EBITDA is derived from Operating Income, which is adjusted for one-time expenses, merger and acquisition and capital raising costs, non-cash related compensation costs, and depreciation and amortization.
| 41 |
Average Basket Size
Average Basket Size is calculated based on the average dollar value of all total items purchased by a single customer during a single visit to one of the Company’s retail dispensary stores. Management monitors and utilizes Average Basket Size to assess consumer preferences and behavior, effectiveness of consistent reward and discount offerings, and product performance. Management believes this metric can be useful to investors for a better understanding of average customer spend and revenue across all Company retail dispensaries.
Recorded Customer Visits
The Recorded Customer Visits metric reports the number of customers that have visited any of the Company’s retail dispensary stores and made a purchase. Customer visits are recorded at the time of purchase. If a customer makes multiple purchases in a day, each purchase is counted as an individual visit. Management uses Recorded Customer Visits to monitor and assess Company performance in the markets where it operates, consumer acceptance of the Company’s brand and products, customer retention, and store traffic. Recorded Customer Visits is a useful non-financial metric for investors to contextualize the Company’s assessment of overall market performance and consumer appetite for cannabis products.
Same Store Sales and Stacked IDs
The Company utilizes Same Store Sales and Stacked Identical Store Sales (“Stacked IDs”) to evaluate and monitor organic growth from existing dispensaries. Management believes these metrics are useful for investors to assess management of our retail stores and to distinguish revenue and growth from operations from revenue and growth from acquisitions. Same Store Sales and Stacked IDs are both expressed as a percentage that indicates the relative increase or decrease to revenue for certain retail stores from the relevant previous reporting period, which are reported separately for retail operations in Colorado and New Mexico. Same Store Sales is calculated by comparing revenue from sales for all dispensaries in existence for more than one year against the revenue from the sales for the same dispensaries for a specified previous period. Stacked IDs, which is derived from Same Store Sales, reflects Same Store Sales as adjusted for dating discrepancies to report comparable sales for the identical period of days for a specified previous period.
Liquidity and Capital Resources
As of June 30, 2022 and December 31, 2021, the Company had total current liabilities of $28,557,632 and $45,263,179, respectively. The decrease is driven by the revaluation of the derivative liability associated with the Investor Notes. As of June 30, 2022 and December 31, 2021, the Company had cash and cash equivalents of $33,862,423 and $106,400,216, respectively to meet its current obligations. The Company had working capital of $38,248,532 as of June 30, 2022, a decrease of $40,400,544 as compared to December 31, 2021. The reduction in working capital is primarily driven by the reduction of cash to fund acquisitions and operations.
The Company is an early-stage growth company, generating cash from revenues and capital raises. Cash is being reserved primarily for capital expenditures, facility improvements and strategic investment opportunities. The Company anticipates overall revenue to increase in 2022 due to acquisitions and adult-use becoming legalized in New Mexico on April 1, 2022. It is possible the Company will seek additional external financing to meet capital needs in the future. The Company relies on internal capital that is generated through revenue and any other internal sources of liquidity to meet its short-term and long-term capital demands as well as various forms of external financing, including loan arrangements, capital raises, and cash from the Investor Notes. The Company maintains the unused portion of the funds received from the Investor Notes for future acquisitions and execution of growth strategies.
Due to our participation in the cannabis industry and the regulatory framework governing cannabis in the United States, our debt and loan arrangements are sometimes subject to higher interest rates than are market for other industries, which has an unfavorable impact on our liquidity and capital resources. Additionally, the cash requirements to service our debt obligations increase with the passage of time due to interest accrual, which increases constraints on our capital resources and tends to reduce liquidity in the amount of such accruals. We currently anticipate meeting these cash requirements from operating revenue and cash on hand. One of our strategic goals is to stimulate growth through acquisitions, which also tends to negatively impact liquidity during periods when we consummate an identified acquisition. We expect to continue executing this strategy in future periods, which will decrease liquidity.
| 42 |
Cash Flows
Cash Provided by (Used in) Operating, Investing and Financing Activities
Net cash provided by (used in) operating, investing and financing activities for the quarters ended June 30, 2022 and 2021 were as follows:
| For the Periods Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Net cash provided by (used in) Operating Activities | $ | (7,961,974 | ) | $ | 1,395,416 | |||
| Net cash used in Investing Activities | (102,910,586 | ) | (67,132,921 | ) | ||||
| Net cash provided by Financing Activities | 38,334,767 | 85,631,039 | ||||||
The Company’s cash provided by (used in) operating activities is predominantly driven by revenue, which is supplemented by increases in sales from acquisitions. Our use of cash from investing activities is driven by acquisition of businesses, cannabis licenses, and property, plant and equipment for existing entities. Our cash provided by financing activities is mainly from proceeds from our credit facility, the Investor Notes and the issuance of shares of Preferred Stock.
CONTRACTUAL CASH OBLIGATIONS AND OTHER COMMITMENTS AND CONTINGENCIES
The following table quantifies the Company’s future contractual obligation as of June 30, 2022:
| Total | 2022 | 2023 | 2024 | 2025 | 2026 | Thereafter | ||||||||||||||||||||||
| Notes Payable (a) | $ | 173,415,366 | $ | – | $ | 2,250,000 | $ | 3,000,000 | $ | 40,651,759 | $ | 127,513,607 | $ | – | ||||||||||||||
| Interest Due on Notes Payable | 70,356,868 | 9,842,341 | 17,410,766 | 17,340,492 | 15,370,549 | 10,392,720 | – | |||||||||||||||||||||
| Right of Use Assets | 24,566,697 | 2,436,876 | 4,230,773 | 4,153,572 | 3,988,575 | 2,993,623 | 6,763,278 | |||||||||||||||||||||
| Total | $ | 268,338,931 | $ | 12,279,217 | $ | 23,891,539 | $ | 24,494,064 | $ | 60,010,883 | $ | 140,899,949 | $ | 6,763,278 | ||||||||||||||
(a) - This amount excludes $44,887,772 of unamortized debt discount and $7,446,718 of unamortized debt issuance costs. See Note 10 - Debt
The Company anticipates using funds from operating activities and, if needed, additional external financing, to support contractual cash obligations.
Off-Balance Sheet Arrangements
As of June 30, 2022 and June 30, 2021, we were not party to any off-balance sheet arrangement that had or was reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, cash requirements or capital resources.
| 43 |
Critical Accounting Estimates and Recent Accounting Pronouncements
The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The Company believes that of its significant accounting policies (see Note 2 to Financial Statements), the ones that may involve a higher degree of uncertainty, judgment and complexity are revenue recognition, stock based compensation, derivative instruments, income taxes, goodwill and commitments and contingencies are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.
Revenue Recognition and Related Allowances
Our revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until the criteria are met. A contract liability is recorded when consideration is received in advance of the delivery of goods or services. We identify revenue contracts upon acceptance from the customer when such contract represents a single performance obligation to sell our products.
We have three main revenue streams: (i) retail sales, (ii) wholesale sales, and (iii) other revenues from revenues from consulting, licensing, and other miscellaneous sources.
The Company’s retail and wholesale sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, we consider several indicators, including significant risks and rewards of products, our right to payment, and the legal title of the products. Based on the assessment of control indicators, our sales are generally recognized when products are delivered to customers.
The Company’s other revenue, typically from licensing and consulting services, is recognized when our obligations to our client are fulfilled which is determined when milestones in the contract are achieved. The Company’s revenue from seminar fees is related to one-day seminars and is recognized as earned upon the completion of the seminar. We also recognize expense reimbursement from clients as revenue for expenses incurred during certain jobs.
Stock Based Compensation
We account for share-based payments pursuant to Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation and, accordingly, we record compensation expense for share-based awards based upon an assessment of the grant date fair value for stock and restricted stock awards using the Black-Scholes option pricing model.
Our stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 when stock or options are awarded for previous or current service without further recourse.
| 44 |
Income Taxes
ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, the Company’s deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
Goodwill and Intangible Assets
Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. We amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 3 to 15 years.
Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry and other risks specific to us. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.
Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.
We performed our annual fair value assessment on our subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets at December 31, 2021, and determined that no impairment exists. No additional factors or circumstances existed as of June 30, 2022, that would indicate impairment.
| 45 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to affect, our internal control over financial reporting.
| 46 |
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
On June 7, 2019, the Company filed a complaint against ACC Industries Inc. and Building Management Company B, L.L.C., in state district court located in Clark County, Nevada, alleging, amongst other causes of action, breach of contract, conversion, and unjust enrichment and seeking general, special and punitive damages. On July 17, 2019, the parties stipulated to stay the case in favor of arbitration. On February 25, 2020, ACC Industries Inc. filed a counterclaim against the Company alleging breach of contract. The Company discovered new facts that lead it to believe that a related entity not previously named as a party to the arbitration, ACC Enterprises, LLC (“ACC”), should be brought in as a party to the arbitration. Based upon the new facts, the Company filed a motion to amend the complaint to add new claims and ACC as a party. On September 1, 2020, the arbitrator granted the Company’s motion and permitted the Company to amend the complaint to add ACC as a party. On September 1, 2020, the Company filed an amended complaint and added intentional misrepresentation, fraudulent inducement, civil conspiracy, aiding and abetting, successor liability and fraudulent concealment claims. The Company began arbitration proceedings on November 2, 2020. The Company completed arbitration in February 2021. On May 14, 2021, the Arbitrator entered an award in favor of the Company in the aggregate amount of $1,935,273, subject to an offset equal to $150,000, for a total net award of $1,785,273. After the arbitration award was entered, a receiver was appointed over ACC and its affiliates due to the death of the only owner who had a valid cannabis establishment registration agent card. An automatic litigation stay was entered upon the appointment of the receiver. During the receivership, ACC's owners have had internal ownership disputes and ACC has had financial difficulties. The receiver has taken the position that ACC should be liquidated and sold. On April 28, 2022, the receiver received approval from the court to liquidate ACC’s assets. On May 24, 2022, upon the completion of a bidding procedure for certain ACC assets, the court approved the sale of certain ACC assets to the only and prevailing bidder. The finality of that sale is in progress and near completion. On July 26, 2022, the court approved a creditors’ claim process. The Company intends to comply with that process and submit a claim for approval. The company continues to actively participate in the receivership case.
On July 6, 2018, the Company filed a complaint in the Eight Judicial Court, Clark County, Nevada against Vegas Valley Growers (“VVG”). In the complaint, the Company alleges breach by VVG of the Technologies License Agreement dated April 27, 2017 entered into between the parties and seeks general, special and punitive damages in the amount of $3,876,850. On August 28, 2018, VVG filed an Answer and Counterclaim against the Company. On August 2, 2019, a jury found in favor of the Company and awarded the Company damages totaling $2,773,321 plus pre- and post-judgment interest and attorneys’ fees. In March 2020, VVG filed its opening appeal brief with the Nevada Supreme Court. The Company’s response brief was due on May 15, 2020. After VVG filed its opening brief in March 2020, the Company filed a Motion to Strike portions of the brief and record. On August 27, 2020, the court ordered VVG to supplement its brief and the record. On October 27, 2020, the Company, in a joint request with VVG, filed a motion to extend its time to file its answering brief. The Company filed its answering brief in January 2021. VVG’s reply brief was filed in March 2021. On July 23, 2021, the Nevada Supreme Court affirmed the trial court’s damage award but remanded the case to the trial court to properly calculate post-judgment interest. After the affirmance, VVG filed a petition for rehearing with the Nevada Supreme Court arguing it overlooked or misapprehended material facts in the record. The Company answered the rehearing petition arguing that it did not. On December 22, 2021, the Company received $3,577,200 for most of the outstanding receivable plus interest and legal fees. Requests for costs and fees related to the appeal are currently pending before the district court.
Item 1A. Risk Factors
There have been no material changes in the risk factors applicable to us from those identified in “Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the period ended December 31, 2021 filed with the Securities and Exchange Commission on March 31, 2022.
| 47 |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The Company is subject to restrictions on the payment of dividends and other working capital requirements in its loan and debt agreements. See Note 11 to the Financial Statements included in Part I to this Quarterly Report on Form 10-Q for additional information on the Company’s indebtedness and related restrictions therein.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits
| 2.1 | Asset and Personal Goodwill Purchase Agreement, dated March 11, 2022, by and among Medicine Man Technologies, Inc., Double Brow, LLC, Urban Health & Wellness, Inc., Patrick Johnson, and Productive Investments, LLC (Incorporated by reference to Exhibit 99.2 to Medicine Man Technologies, Inc.’s Current Report on Form 8-K filed June 6, 2022 (Commission File No. 00055450)) | |
| 10.1*** | Form of Stock Award Agreement, dated June 14, 2022, between Director and Medicine Man Technologies, Inc. | |
| 10.2*** | Stock Award Agreement, dated June 24, 2022, between Jonathan Berger and Medicine Man Technologies, Inc. | |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer | |
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | |
| 32* | Chief Executive Officer and Chief Financial Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101) |
______________________
+ Certain exhibits and schedules to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.
* Furnished herewith.
** Indicates management contract or compensatory plan or arrangement.
| 48 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: August 11, 2022 | MEDICINE MAN TECHNOLOGIES, INC. |
| By: /s/ Justin Dye | |
|
Justin Dye, Chief Executive Officer (Authorized Officer) | |
| By: /s/ Nancy Huber | |
| Nancy Huber, Chief Financial Officer | |
| (Principal Financial Officer and Chief Accounting Officer) |
| 49 |
Exhibit 10.1
Schedule of Omitted Documents and Terms
The Form of Stock Award Agreement attached to this Quarterly Report on Form 10-Q was entered into between the Company and certain Directors to formalize compensation for service as a member of the Board of Directors. The below chart identifies the relevant documents omitted from this Quarterly Report on Form 10-Q and material deviations from the Form of Stock Award Agreement attached hereto.
Document Omitted |
Terms of Award |
Stock Award Agreement, dated June 14, 2022, between the Company and Paul Montalbano
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Jonathan Berger
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Jeffrey Cozad
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Pratap Mukharji
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Jeff Garwood
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Brian Ruden
|
22,728 Shares of Common Stock |
Stock Award Agreement, dated June 14, 2022, between the Company and Salim Wahdan
|
14,584 Shares of Common Stock |
Stock Award Agreement, dated June 24, 2022, between the Company and Salim Wahdan
|
15,586 Shares of Common Stock |
| 1 |
Medicine Man Technologies, Inc.
2017 Equity Incentive Plan
Stock Award Agreement
This Stock Award Agreement (this “Agreement”) is made and entered into as of [DATE], by and between Medicine Man Technologies, Inc., d/b/a Schwazze, a Nevada corporation (the “Company”), and [DIRECTOR NAME], who is a member of the Board of Directors of the Company (the “Participant”) under and in accordance with the Medicine Man Technologies, Inc. 2017 Equity Incentive Plan, as amended (the “Plan”).
1. Award of Shares.
1.1 Grant. The Company hereby grants to the Participant this Stock Award, for service as a director of the Company previously rendered and to be rendered during the year in which this Agreement is executed. Pursuant to this Stock Award, the Participant is entitled to receive the number of shares of Common Stock of the Company equal to the “Determined Amount.” For purposes of this Agreement and the Plan, the “Determined Amount” means the number of shares of Common Stock (rounded down to the nearest whole share) equal to (a) $[__] divided by (b) the closing price of the Common Stock on [DATE]. For clarity, this Agreement hereby makes an award of [__] shares of Common Stock (that is, $[__] divided by $[SHARE PRICE]) to the Participant (the “Awarded Shares”).
1.2 Consideration. The Stock Award being made pursuant to this Agreement and under the Plan is intended to (a) attract and retain highly qualified individuals to serve as directors of the Company, (b) increase non-employee directors’ stock ownership in the Company and (c) align non-employee directors’ financial interests more closely with those of the stockholders of the Company.
1.3 Plan Document Governs. The Awarded Shares and this Agreement are subject to all of the applicable terms and conditions of the Plan as approved by the Company’s stockholders. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail. Capitalized words and phrases used but not defined herein will have the meaning ascribed to them in the Plan.
1.4 Additional Agreements. Participant agrees upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of the Award.
2. Payment for the Awarded Shares. The Participant shall not be required to make any payment for the Awarded Shares granted under this Agreement.
3. Vesting. Subject to the transfer restrictions under this Agreement, the Plan and the Company’s governing documents, the Participant shall have full beneficial ownership of, and rights and privileges of a shareholder as to Awarded Shares, including the right to vote and the right to receive dividends.
| 2 |
4. Issuance of Shares.
4.1 Timing of Issuance. As soon as administratively practicable after this Agreement is fully executed, the Company shall issue the shares of Common Stock representing the Awarded Shares registered in the name of the Participant, the Participant’s authorized assignee, or the Participant’s legal representative, which issuance shall be evidenced by stock certificates representing the shares with the appropriate legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the Company.
4.2 Issuance Subject to Government and Other Regulations. The obligation of the Company to deliver the shares of Common Stock awarded under this Agreement and the Plan shall be subject to all applicable laws, rules and regulations and such approvals by any governmental agencies or regulatory authorities as may be required or be deemed necessary or appropriate by counsel for the Company.
5. Stockholder Rights. The Participant shall not have any rights as a stockholder of the Company with respect to the Awarded Shares of Common Stock unless and until certificates representing the shares have been issued by the Company to the Participant as the holder of such shares, or the shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.
6. Limitations on Transfer.
6.1 Transferability. The Participant will not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Awarded Shares except in compliance with this Agreement, the Company’s bylaws, any stockholders’ agreement that the Participant may be required to execute, applicable securities laws or Company or underwriter trading policies. For clarity, no sale, transfer or other disposition of the Awarded Shares or any interest in the Awarded Shares may occur unless the Company has first determined that such sale, transfer or other disposition is permitted by applicable securities laws (even if otherwise allowed by this Agreement and the Company’s corporate governance documents).
6.2 Restrictive Legends. Certificates for the Awarded Shares may include any legend which the Company deems appropriate to reflect any or all of the applicable restrictions on transfers.
6.3 Stop-Transfer Orders. The Participant agrees that, in order to ensure compliance with the restrictions referred to herein and the Plan, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. In addition, the Company shall not be required (i) to transfer on its books any Awarded Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the Plan or other governing document or (ii) to treat as the owner or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Awarded Shares shall have been so transferred.
7. Adjustments. If the outstanding Common Stock shall at any time be changed or exchanged by exchanges of shares, recapitalization, merger, consolidation or other corporate reorganization in which the Company is the surviving corporation, the number of Awarded Shares may be adjusted or terminated in any manner as contemplated by Section 11 of the Plan.
| 3 |
8. Withholding; Tax Liability.
8.1 Withholding. If the Company, in its discretion, determines that it is obligated to withhold any tax in connection with the grant of the Awarded Shares to the Participant, the Participant must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal, state or local tax withholding obligation relating to the Awarded Shares by any of the following means or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the award made pursuant to this Agreement; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock. The Company has the right to withhold taxes from any compensation paid to a Participant.
8.2 Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or any other action related to the Awarded Shares or the subsequent sale of any of the Award Shares and (b) does not commit to structure the award made under this Agreement and pursuant to the Plan to reduce or eliminate the Participant’s liability for Tax-Related Items.
8.3 The Participant understands and agrees that (a) the Company will only recognize the Participant as a record holder of the Awarded Shares if the Participant has paid or made, prior to any relevant taxable or tax withholding event, as applicable, adequate arrangements satisfactory to the Company to satisfy any withholding obligation the Company may have for Tax-Related Items and (b) the Company has no obligation to deliver the Awarded Shares to or on behalf of the Participant until the Participant has satisfied the obligations in connection with the Tax-Related Items.
9. Leak Out. All shares of Common Stock issued pursuant to this Agreement may be liquidated at a daily rate of no more than 5% of the preceding 5 day average volume of the Company’s Common Stock on any given trading day.
10. Award Subject to Company Clawback or Recoupment. To the extent permitted by applicable law, the Awarded Shares shall be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of your employment or other service that is applicable to the Participant. In addition to any other remedies available under such policy, applicable law may require the cancellation of this Stock Bonus Award and the recoupment of any gains realized with respect to the Stock Bonus Award described in this Agreement.
11. Compliance with Law. The issuance and transfer of shares of Common Stock pursuant to this Agreement shall be subject to compliance by the Company and the Participant with all applicable requirements of federal and state securities laws, regulatory agencies and any stock exchange or other trading market on which the Company’s shares of Common Stock may be listed or quoted. No shares of Common Stock shall be issued pursuant to this Agreement unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register the shares of Common Stock with the U.S. Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.
12. Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the General Counsel of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the Company. Either party hereto may designate another address in writing (or by such other method approved by the Company) from time to time.
| 4 |
13. Governing Law. This Agreement will be governed by, construed and enforced in accordance with the internal laws of the State of Nevada without regard to conflict of law principles.
14. Venue and Jurisdiction. Notwithstanding Section 13 of this Agreement and Section 12(E) (“Choice of Law”) of the Plan, except as the laws of the United States may otherwise require, any and all disputes relating to or arising under this Agreement to enforce this Agreement shall be brought by civil action and resolved only in the United States District Court for the District of Colorado (the “Court”), which shall have and retain continuing and exclusive jurisdiction over this Agreement. The Participant, by virtue of his or her participation in the Plan, irrevocably consents to the jurisdiction and venue in the Court, and that any and all disputes shall be adjudicated solely by the Court, and further irrevocably waive any objection or defense based on lack of venue, personal jurisdiction, forum non conveniens, transfer, priority doctrines, and any defense(s) of similar type or import.
15. Interpretation. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements, representations and understandings. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the full Board for review. The resolution of such dispute by the Board shall be final and binding on the Participant and the Company.
16. Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to whom this Agreement may be transferred by will or the laws of descent or distribution.
17. Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Stock Award in this Agreement does not create any contractual right or other right to receive any shares of Common Stock or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s service with the Company.
18. Amendment. The Board has the right to amend, alter, suspend, discontinue or cancel this Award made pursuant to this Agreement, prospectively or retroactively; provided, that, no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s consent.
19. Acknowledgement and Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan together with this Agreement, and any applicable Plan prospectus. The Participant represents that he or she has read and understands the terms and provisions thereof, and accepts this Award subject to all of the terms and conditions of the Plan and this Agreement. The Participant acknowledges that there may be adverse tax consequences upon receipt of the shares of Common Stock issued pursuant to this Agreement or disposition of the shares of Common Stock and that the Participant should consult the Participant’s personal tax advisor prior to such receipt or disposition. In accepting this Award and executing this Agreement, the Participant agrees to accept as binding, conclusive and final all decisions or interpretations of the Company upon any questions relating to the Plan and this Agreement.
20. Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.
21. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which, when taken together, will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
[Remainder of Page Intentionally
Left Blank;
Signature Page Follows]
| 5 |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the date first above written notwithstanding the actual date of signing.
| COMPANY: | |
| Medicine Man Technologies, Inc., d/b/a/ Schwazze, | |
| a Nevada corporation | |
| By: ________________________________ | |
| Name: ______________________________ | |
Title: _______________________________ | |
| PARTICIPANT: | |
| ______________________________________ | |
| Printed Name: ___________________________ |
CONSENT OF SPOUSE OR REPRESENTATION OF UNMARRIED STATUS
Consent of Spouse: The undersigned spouse of the Participant has read and hereby approves the foregoing Stock Award Agreement. In consideration of the Company’s granting the Participant the right to acquire the Awarded Shares in accordance with the terms of the Stock Award Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of the Stock Award Agreement, including (without limitation) the right of the Company (or its assigns) to take actions that may affect the Participant’s ownership of the Awarded Shares.
|
______________________________________
______________________________________
|
Dated as of ____________________, 2022 |
♦ ♦ ♦
Representation of Unmarried Status: By signing below, I, the above-named Participant, represent that, as of the Effective Date, I am single and not married, including under common law.
| ______________________________________ | |
| Printed Name: ___________________________ | |
| Date: _________________________________ |
| 6 |
Medicine Man Technologies, Inc. 2017 Equity Incentive Plan, as amended
[Attached]
| 7 |
Amended and Restated Prospectus
[Attached]
| 8 |
Exhibit 10.2
Medicine Man Technologies, Inc.
2017 Equity Incentive Plan
Stock Award Agreement
This Stock Award Agreement (this “Agreement”) is made and entered into as of June 24, 2022, by and between Medicine Man Technologies, Inc., d/b/a Schwazze, a Nevada corporation (the “Company”), and Jonathan Berger, who is a member of the Board of Directors of the Company (the “Participant”) under and in accordance with the Medicine Man Technologies, Inc. 2017 Equity Incentive Plan, as amended (the “Plan”).
1. Award of Shares.
1.1 Grant. The Company hereby grants to the Participant this Stock Award, for service as a Chair of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board of Directors of the Company (the “Board”) previously rendered and to be rendered during the year in which this Agreement is executed. Pursuant to this Stock Award, the Participant is entitled to receive the number of shares of Common Stock of the Company equal to the “Determined Amount.” For purposes of this Agreement and the Plan, the “Determined Amount” means the number of shares of Common Stock (rounded up to the nearest whole share) equal to (a) $12,000 divided by the closing price of the Common Stock on June 16, 2022 for service as Chair of the Audit Committee of the Board, plus (b) $8,000 divided by the closing price of the Common Stock on June 16, 2022 for service as Chair of the Compensation Committee of the Board, plus (c) $5,000 divided by the closing price of the Common Stock on June 16, 2022 for service as Chair of the Nominating and Corporate Governance Committee of the Board. For clarity, this Agreement hereby makes an award of 19,085 shares of Common Stock (that is, $25,000 divided by $1.31), to the Participant (the “Awarded Shares”).
1.2 Consideration. The Stock Award being made pursuant to this Agreement and under the Plan is intended to (a) attract and retain highly qualified individuals to serve as directors of the Company and chair Board committees, (b) increase non-employee directors’ stock ownership in the Company and (c) align non-employee directors’ financial interests more closely with those of the stockholders of the Company.
1.3 Plan Document Governs. The Awarded Shares and this Agreement are subject to all of the applicable terms and conditions of the Plan as approved by the Company’s stockholders. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail. Capitalized words and phrases used but not defined herein will have the meaning ascribed to them in the Plan.
1.4 Additional Agreements. Participant agrees upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of the Award.
2. Payment for the Awarded Shares. The Participant shall not be required to make any payment for the Awarded Shares granted under this Agreement.
3. Vesting. Subject to the transfer restrictions under this Agreement, the Plan and the Company’s governing documents, the Participant shall have full beneficial ownership of, and rights and privileges of a shareholder as to Awarded Shares, including the right to vote and the right to receive dividends.
| 1 |
4. Issuance of Shares.
4.1 Timing of Issuance. As soon as administratively practicable after this Agreement is fully executed, the Company shall issue the shares of Common Stock representing the Awarded Shares registered in the name of the Participant, the Participant’s authorized assignee, or the Participant’s legal representative, which issuance shall be evidenced by stock certificates representing the shares with the appropriate legends affixed thereto, appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the Company.
4.2 Issuance Subject to Government and Other Regulations. The obligation of the Company to deliver the shares of Common Stock awarded under this Agreement and the Plan shall be subject to all applicable laws, rules and regulations and such approvals by any governmental agencies or regulatory authorities as may be required or be deemed necessary or appropriate by counsel for the Company.
5. Stockholder Rights. The Participant shall not have any rights as a stockholder of the Company with respect to the Awarded Shares of Common Stock unless and until certificates representing the shares have been issued by the Company to the Participant as the holder of such shares, or the shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.
6. Limitations on Transfer.
6.1 Transferability. The Participant will not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Awarded Shares except in compliance with this Agreement, the Company’s bylaws, any stockholders’ agreement that the Participant may be required to execute, applicable securities laws or Company or underwriter trading policies. For clarity, no sale, transfer or other disposition of the Awarded Shares or any interest in the Awarded Shares may occur unless the Company has first determined that such sale, transfer or other disposition is permitted by applicable securities laws (even if otherwise allowed by this Agreement and the Company’s corporate governance documents).
6.2 Restrictive Legends. Certificates for the Awarded Shares may include any legend which the Company deems appropriate to reflect any or all of the applicable restrictions on transfers.
6.3 Stop-Transfer Orders. The Participant agrees that, in order to ensure compliance with the restrictions referred to herein and the Plan, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. In addition, the Company shall not be required (i) to transfer on its books any Awarded Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the Plan or other governing document or (ii) to treat as the owner or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Awarded Shares shall have been so transferred.
7. Adjustments. If the outstanding Common Stock shall at any time be changed or exchanged by exchanges of shares, recapitalization, merger, consolidation or other corporate reorganization in which the Company is the surviving corporation, the number of Awarded Shares may be adjusted or terminated in any manner as contemplated by Section 11 of the Plan.
| 2 |
8. Withholding; Tax Liability.
8.1 Withholding. If the Company, in its discretion, determines that it is obligated to withhold any tax in connection with the grant of the Awarded Shares to the Participant, the Participant must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal, state or local tax withholding obligation relating to the Awarded Shares by any of the following means or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the award made pursuant to this Agreement; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock. The Company has the right to withhold taxes from any compensation paid to a Participant.
8.2 Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or any other action related to the Awarded Shares or the subsequent sale of any of the Award Shares and (b) does not commit to structure the award made under this Agreement and pursuant to the Plan to reduce or eliminate the Participant’s liability for Tax-Related Items.
8.3 The Participant understands and agrees that (a) the Company will only recognize the Participant as a record holder of the Awarded Shares if the Participant has paid or made, prior to any relevant taxable or tax withholding event, as applicable, adequate arrangements satisfactory to the Company to satisfy any withholding obligation the Company may have for Tax-Related Items and (b) the Company has no obligation to deliver the Awarded Shares to or on behalf of the Participant until the Participant has satisfied the obligations in connection with the Tax-Related Items.
9. Leak Out. All shares of Common Stock issued pursuant to this Agreement may be liquidated at a daily rate of no more than 5% of the preceding 5 day average volume of the Company’s Common Stock on any given trading day.
10. Award Subject to Company Clawback or Recoupment. To the extent permitted by applicable law, the Awarded Shares shall be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of your employment or other service that is applicable to the Participant. In addition to any other remedies available under such policy, applicable law may require the cancellation of this Stock Bonus Award and the recoupment of any gains realized with respect to the Stock Bonus Award described in this Agreement.
11. Compliance with Law. The issuance and transfer of shares of Common Stock pursuant to this Agreement shall be subject to compliance by the Company and the Participant with all applicable requirements of federal and state securities laws, regulatory agencies and any stock exchange or other trading market on which the Company’s shares of Common Stock may be listed or quoted. No shares of Common Stock shall be issued pursuant to this Agreement unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register the shares of Common Stock with the U.S. Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.
12. Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the General Counsel of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the Company. Either party hereto may designate another address in writing (or by such other method approved by the Company) from time to time.
| 3 |
13. Governing Law. This Agreement will be governed by, construed and enforced in accordance with the internal laws of the State of Nevada without regard to conflict of law principles.
14. Venue and Jurisdiction. Notwithstanding Section 13 of this Agreement and Section 12(E) (“Choice of Law”) of the Plan, except as the laws of the United States may otherwise require, any and all disputes relating to or arising under this Agreement to enforce this Agreement shall be brought by civil action and resolved only in the United States District Court for the District of Colorado (the “Court”), which shall have and retain continuing and exclusive jurisdiction over this Agreement. The Participant, by virtue of his or her participation in the Plan, irrevocably consents to the jurisdiction and venue in the Court, and that any and all disputes shall be adjudicated solely by the Court, and further irrevocably waive any objection or defense based on lack of venue, personal jurisdiction, forum non conveniens, transfer, priority doctrines, and any defense(s) of similar type or import.
15. Interpretation. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements, representations and understandings. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the full Board for review. The resolution of such dispute by the Board shall be final and binding on the Participant and the Company.
16. Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to whom this Agreement may be transferred by will or the laws of descent or distribution.
17. Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Stock Award in this Agreement does not create any contractual right or other right to receive any shares of Common Stock or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s service with the Company.
18. Amendment. The Board has the right to amend, alter, suspend, discontinue or cancel this Award made pursuant to this Agreement, prospectively or retroactively; provided, that, no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s consent.
19. Acknowledgement and Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan together with this Agreement, and any applicable Plan prospectus. The Participant represents that he or she has read and understands the terms and provisions thereof, and accepts this Award subject to all of the terms and conditions of the Plan and this Agreement. The Participant acknowledges that there may be adverse tax consequences upon receipt of the shares of Common Stock issued pursuant to this Agreement or disposition of the shares of Common Stock and that the Participant should consult the Participant’s personal tax advisor prior to such receipt or disposition. In accepting this Award and executing this Agreement, the Participant agrees to accept as binding, conclusive and final all decisions or interpretations of the Company upon any questions relating to the Plan and this Agreement.
20. Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.
21. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which, when taken together, will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
[Remainder of Page Intentionally
Left Blank;
Signature Page Follows]
| 4 |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the date first above written notwithstanding the actual date of signing.
| COMPANY: | ||
| Medicine Man Technologies, Inc., d/b/a/ Schwazze, | ||
| a Nevada corporation | ||
| By: | /s/ Daniel R. Pabon | |
| Name: | Daniel R. Pabon | |
Title: |
General Counsel | |
| PARTICIPANT: | ||
| /s/ Jonathan Berger | ||
| Printed Name: Jonathan Berger | ||
| 5 |
Medicine Man Technologies, Inc. 2017 Equity Incentive Plan, as amended
[Attached]
| 6 |
Amended and Restated Prospectus
[Attached]
| 7 |
Exhibit 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
I, Justin Dye, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and | |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Dated: August 11, 2022 | /s/ Justin Dye |
|
Justin Dye, Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
I, Nancy Huber, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and | |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Dated: August 11, 2022 | /s/ Nancy Huber |
|
Nancy Huber, Chief Financial Officer (Principal Financial Officer) |
Exhibit 32
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this quarterly report of Medicine Man Technologies, Inc. (the “Company”) on Form 10-Q for the fiscal period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: August 11, 2022 | /s/ Justin Dye |
| Justin Dye, Chief Executive Officer | |
| Dated: August 11, 2022 | /s/ Nancy Huber |
| Nancy Huber, Chief Financial Officer |